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A significant proportion of human immunodeficiency virus type 1 (HIV)-positive 
individuals are affected by the cognitive, motor and behavioural dysfunction that 
characterises HIV associated neurocognitive disorders. While the molecular aetiology 
of this important HIV complication remains largely uncharacterised, HIV 
transactivator of transcription (HIV-Tat) has been identified as a plausible aetiological 
cause. Here we have used mass spectrometry-based discovery proteomics to identify 
the quantitative, cell-wide changes that occur when non-transformed, differentiated 
human neurons are treated with HIV-Tat over time, as a novel cell culture model 
representing the initial progression of HIV associated neurocognitive disorders, and as 
a means to identify putative biomarkers for the illness. We found that our stem cell-
based model system displayed morphological and functional neuronal properties and 
using a Q-Exactive mass spectrometer, we identified over 4000 protein groups (FDR 
< 0.01) in this system with 131,118 and 45 protein groups differentially expressed at 
6, 24 and 48 hours post treatment, respectively. We found changes to the gene 
expression machinery (nucleic acid binding proteins), which suggests that HIV-Tat is 
involved in preparing the host cell for altered transcriptional and translational activity. 
We also found cytoskeletal dysregulation in response to HIV-Tat treatment. The 24-
hour time point of the time course experiment was largely corroborated with a repeat 
experiment. A repeat of the entire time course experiment at a lower cell confluence 
showed that the effect of HIV-Tat treatment to the gene expression machinery was 
unchanged by cell confluence, while the effect to cytoskeletal proteins upon HIV-Tat 
treatment was present, but less prominent, in lower cell confluence samples. We 
hypothesise that the gene-expression-machinery effect may be a biphasic response. 
We further hypothesise that cytoskeletal dysregulation may form part of the molecular 
mechanism responsible for synaptic injury - as the cytoskeleton is crucial for synapse 
development and maintenance - and may contribute to memory impairment in HIV 
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1.1 HIV associated neurocognitive disorders 
South Africa’s burden of human immunodeficieny virus type 1 (HIV) infection is well 
known with a staggering 11.2% of the country’s population (corresponding to 6.19 
million people) infected with the virus (Department of Health 2015). While the 
introduction of highly active antiretroviral therapy (HAART) in 1996 has greatly 
reduced HIV-related mortality and has improved quality of life for HIV-positive 
individuals, HIV associated comorbidities persist and present a challenge for those 
treating and living with HIV infection (Brew 2004). One group of complications that 
affects up to 60% of HIV-positive South Africans, are the HIV associated 
neurocognitive disorders (HAND) (Joska, Westgarth-Taylor, Hoare, et al. 2011). This is 
a group of disorders resulting from HIV infection of the central nervous system (CNS), 
characterised by varying degrees of cognitive, motor, and behavioural dysfunction 
(Antinori et al. 2007).  
While HAART has mediated a shift toward less severe forms of HAND, the 
prevalence of HAND remains high due to a number of factors, including the increased 
longevity afforded by HAART, incomplete penetrance of antiretroviral drugs into the 
CNS (allowing for long-term viral replication and subsequent neurotoxicity), and 
potential antiretroviral-mediated neurotoxicity (Brew 2004; Simioni et al. 2010; 
Letendre et al. 2008; Valcour et al. 2004; Ances et al. 2010; Marra et al. 2010).  
There is some concern that the abovementioned prolonged CNS exposure to HIV 
and to antiretroviral drugs may compound the long-term adverse effects of HIV 
infection on neurocognitive functioning, specifically, accelerating neurocognitive aging 
(Holt et al. 2012). In fact, such premature aging as the result of HIV infection may 
represent a more pressing global health issue in the HAART era than frank 
neurocognitive impairment. That said the more severe symptoms of HAND are still 
relevant, especially in developing countries such as South Africa. Here, 25% of HIV 
positive patients are diagnosed with the most severe form of HAND (HIV associated 
dementia (HAD)) upon commencement of HAART therapy (Joska, Westgarth-Taylor, 
Myer, et al. 2011). The high prevalence of HAD in South Africa upon initiation of 




that HIV positive patients typically qualify for antiretroviral treatment only during late-
stage infection (Department of Health 2013), at which point cognitive decline may 
already be present or may already have progressed (Joska, Westgarth-Taylor, Hoare, et 
al. 2011). 
In all its forms, HAND contributes significantly to the South African healthcare 
(and ultimately economic) burden. This is largely due to the high prevalence of HIV 
infection (Department of Health 2015) translating into HAND being the leading cause 
of dementia in South Africa (Joska, Westgarth-Taylor, Myer et al. 2011; Joska et al. 
2011; Nath et al. 2008). The aging HIV-positive population - as a result of the increased 
longevity afforded by HAART (Brew 2004) and the stabilizing infection rate (UNAIDS 
2013) - incentivises the standardization of diagnosis and prognosis of HAND [for 
example, by identifying predictive markers of disease progression (De Jager et al. 
2015)], as well as the identification of drug targets in order to develop novel long-term 
HAND therapeutic strategies. As HIV enters the CNS early after initial infection (Haase 
1986; Fischer-Smith et al. 2001), diagnosis and treatment of HAND are thought to be 
more beneficial strategies than prevention. 
 
1.2 Current HAND diagnosis and treatment 
HAND is largely a diagnosis of exclusion in HIV-positive individuals with impairment 
in multiple cognitive domains (e.g. attention, working memory) (Antinori et al. 2007). 
Further, at present, no rapid, reliable diagnosis or specific treatment exists for HAND, 
and the exact molecular dysregulation underlying neurocognitive symptoms is largely 
uncharacterised. Current diagnostic tools and treatments offer varying levels of 
practicality and have been used with mixed success. 
For example, while the international HIV dementia scale (IHDS) is a diagnostic 
test that may be quickly administered and is claimed to be free of cultural bias (Sacktor 
et al. 2005), it has low accuracy especially for the correct diagnosis of subtle forms of 
HAND and may be fundamentally flawed due to the absence of a diagnostic gold 
standard (Haddow et al. 2013). In another HAND diagnostic example, functional 
magnetic resonance imaging (fMRI) - which measures blood flow as a proxy for brain 
function - has been suggested as a HAND risk-stratification tool (Holt 2012, Ances et 
al., 2010). However, given that fMRI is expensive, specialised, and not routinely 
performed in South Africa, this may not be a viable option in our context. Therefore, 
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there is a need to identify specific, predictive biomarkers of HAND, which may be 
detectable by more readily available and inexpensive means. In addition, to facilitate 
specific biomarker identification (as well as rational drug design), a more detailed 
understanding of the molecular pathology of HAND is required. 
In an example of molecular pathology informing treatment, lithium has been used 
to treat HAND based on one of its proposed mechanisms of action - the targeting and 
inhibition of glycogen synthase kinase 3 beta (GSK3) (an important factor in apoptosis 
induction) - combined with the observation that in vitro treatment of neurons with a 
known HIV virulence factor, HIV transactivator of transcription (HIV-Tat), leads to 
phosphorylation and up-regulation of GSK3’s activity (Brown & Tracy 2013; Forde & 
Dale 2007; Maggirwar et al. 1999; Rao et al. 2013). Furthermore, in vitro treatment with 
lithium has been shown to block HIV-Tat-mediated apoptosis of neuroblastoma cells 
(Ganief, unpublished). However, while lithium treatment has yielded some success 
regarding improvement of HAND symptoms during clinical trials (Letendre et al. 2006), 
as well as improvement of brain network connectivity in humans in vivo (Tivarus et al. 
2015), apoptosis-inhibited cells may yet be maintained in a neurodegenerative state post-
treatment. In addition, lithium has a very narrow therapeutic window, an undesirable 
adverse effect profile, and long-term exposure to lithium in the context of HIV infection 
is not well characterised. 
Identification of ‘upstream’ drug targets may facilitate reversion of a 
neurodegenerative to a normal phenotype, thereby preventing progression of 
degeneration and improving prognosis. Furthermore, elucidating the exact molecular 
pathology of the disease, as it progresses over time, may reveal prognostic markers for 
HAND. Used clinically, such markers may inform at which point after HIV infection 
HAART should ideally be initiated, and could aid in the identification of possible drug 
targets for adjuvant therapy for treatment of neurocognitive sequelae.  
1.3 Plausible molecular origins of HAND 
Of particular importance in elucidating the molecular pathology of HAND is an 
improved understanding of the actions of HIV-Tat, as mentioned a known neurovirulent 
factor (Rao et al. 2013). To contextualise HIV-Tat’s role in HAND, however, it is also 




all plausible molecular origins of HAND as the true aetiology is most likely 
multifactorial. 
It is well understood that HIV crosses the highly selective blood brain barrier 
(BBB) early during infection, undetected within peripheral monocytes, which 
periodically enter the CNS to replenish the brain perivascular macrophage population 
('Trojan Horse' model, first proposed by Haase 1986) (Figure 1.1). Indeed, in situ 
hybridisation analysis reveals that HIV antigens co-localise with monocytes, suggesting 
that HIV does target monocytes for infection in the periphery (Fischer-Smith et al. 
2001). Further, HIV infected monocytes show greater chemotaxis in response to the 
chemokine ligand 2 (ccl2) than uninfected monocytes, which suggests that HIV 
contributes to the movement of HIV-infected monocytes into the CNS (Williams et al. 
2013). 
Less clear is the degree to which individual HIV-derived molecules and secondary 
effects contribute to HAND progression. However, the clinical characteristics of HAND 
(Manji et al. 2013) suggest a subset of likely molecular origins, such as HIV-related or 
antiretroviral-mediated. Regarding the former, HIV infection of primary CNS cells, and 
the subsequent inflammatory response, produces products toxic to neurons when present 
at elevated levels, and HIV proteins themselves are able to enter neurons and affect 
neuronal functioning (Figure 1.2 and 1.3). Regarding the latter, antiretroviral drugs are 
able to penetrate the BBB or enter the CNS after prolonged inflammation-induced 
degradation of the BBB, and may have neurotoxic effects (Martín-García et al. 2002) 
(Figure 1.4). It is important to note, however, that the contribution of antiretroviral 
drugs to HAND progression is the least-studied and most widely contested possible 
origin of HAND, and is beyond the scope of this thesis. 
As neurons do not display the CD4 cell surface receptors required for HIV entry, 
HIV must affect neurons via the abovementioned indirect mechanisms (Martín-García 
et al. 2002). While it is important to characterise the effects of all of these etiologies 
individually as well as together (the contribution of each may be patient-specific and 
may inform an individualized treatment plan), HIV-Tat has been shown to be 
particularly important in HAND pathogenesis across most (if not all) patients, as 







Figure 1. Entry of HIV into the CNS and its subsequent effects HIV crosses the BBB undetected, 
shuttled within peripheral monocytes, which enter the CNS to differentiate into macrophages ('Trojan 
Horse' model: Haase 1986; Williams et al. 2013) (1). Once inside the CNS, HIV cannot enter neurons 
via the canonical ‘host CD4 cell surface receptor - HIV-gp120’ entry, as neurons do not display CD4 
cell surface receptors (Martín-García et al. 2002). HIV must therefore affect neurons by alternate 
mechanisms either indirectly (2), by triggering and sustaining an inflammatory response within the 
CNS, the mediators and products of which are toxic to neurons, or directly (3), through the action of 
HIV proteins on neurons themselves, such as HIV-Tat (Martín-García et al. 2002). Certain 
antiretroviral drugs are able to penetrate the BBB (4) to cause neurotoxicity, or are able to enter the 
CNS after HIV mediated degradation of the BBB. Degradation of the BBB occurs through the action 
of HIV proteins (e.g. HIV-Tat) themselves, or through the action of certain chemokines (e.g. ccl2) 
which are up regulated during the HIV-induced inflammatory response (Robertson et al. 2013; Roberts 
et al. 2012). Note: HIV particles are depicted as red stars, ROS – reactive oxygen species; TNF - 
tumor necrosis factor alpha (a cytokine); tat - HIV-Tat; ARV - antiretroviral drug. Double arrow 
indicates differentiation. Question mark - unclear exactly how these agents enter the CNS. 
  
1.4 HIV-Tat: structure, function and role in HAND pathogenesis 
HIV-Tat is a 86-101 residue protein comprising two exons; the first contains all known 
functional regions of the protein and is highly conserved (72 amino acid residues) and 
the second is of variable length (depending on the HIV subtype) and unknown function 
(Figure 2a) (Tahirov et al. 2010). The cysteine rich region of HIV-Tat, located within 
exon 1, is crucial to its transcription factor activity. These amino acids contribute to the 
formation of a unique zinc finger motif that recognizes and binds directly to HIV-Tat’s 
crucial host cofactor, human positive transcription elongation factor (P-TEFb), which 
comprises cyclin-dependant kinase 9 (CDK9) and cyclin T (Ott et al. 2011). The zinc 
finger motif - made up of helices that coordinate 2 zinc ions - is formed by 
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intramolecular disulphide linkages between cysteine residues together with the adjacent 
core region of HIV-Tat (Tahirov et al. 2010). However, cysteine rich regions on 
adjacent HIV-Tat molecules may form intermolecular disulphide linkages that disrupt 
this crucial motif and render the protein inactive (Figure 2b) (Tosi et al. 2000) - an 
important consideration when working with this protein experimentally.  
No consensus exists for the mechanism by which free HIV-Tat crosses the cell 
membrane, but it is accepted that HIV-Tat readily enters cells and accumulates in the 
nucleus [due to its nuclear localisation signal (Figure 2a)] - a feature exploited in the 
development of a drug delivery system, appropriately named ‘cell penetrating peptides’ 
(Richard et al. 2005; Herce & Garcia 2007; Duchardt et al. 2007). In HIV-infected cells, 
HIV-Tat enhances HIV transcription elongation by recruiting host transcription 
machinery - such as P-TEFb - to the viral transactivation response (TAR) RNA 
(Gatignol 2007). P-TEFb bound to HIV-Tat allows viral transcription elongation to 
proceed from the nascent viral RNA by phosphorylating the C-terminal domain of host 
RNA polymerase II, which, in turn, allows for further recruitment of host transcription 
machinery to the viral genome (Ott et al. 2011).  
In uninfected cells, HIV-Tat may still affect transcription by binding to accessible 
host cognate cites (Marban et al. 2011). Indeed, a genome-wide chromatin 
immunoprecipitation sequencing (ChIP-seq) experiment revealed that HIV-Tat 
extensively binds the host genome of T lymphocytes (Marban et al. 2011). Further, 
specific host factors have exhibited altered gene expression as a result of HIV-Tat 
treatment in vitro (Flores et al. 1993; Buonaguro et al. 1994). In addition, due to the 
flexible nature of HIV-Tat (both structurally and functionally), and the fact that it has 
many binding partners (Debaisieux et al. 2012), HIV-Tat may additionally affect 
transcription by recruiting distinct factors to the site of host transcription. Indeed, HIV-
Tat is able to recruit chromatin-modifying proteins such as the histone acetylases p300 
and CREB binding protein (CBP), thus facilitating relaxation of chromatin structure and 
subsequent increased transcription (Gatignol 2007). This presumably facilitates 
increased HIV replication. In this way, HIV-Tat may directly modulate host 
transcription, and subsequent translation, resulting in global changes to host-cell 
function. 
In support of HIV-Tat’s importance as a HAND virulence factor, the level of HIV 
neurovirulence has been directly linked to an HIV-Tat protein dicysteine motif at 




(Rao et al. 2013). Even for classically non-neurovirulent clade C HIV [which 
predominates in Sub-Saharan Africa (Peeters et al. 2003)], the correlation holds. That is 
to say that while a cysteine-serine motif at position 30-31 is usually associated with 
clade C virus (and non-neurovirulence), the abovementioned dicysteine motif is present 
in clade C virus isolated from HAND patients (Rao et al. 2013; Kandathil et al. 2009). 
In addition, in vitro assays show that, in comparison to clade C HIV-Tat with the CS 
motif, clade C HIV-Tat with the CC motif induces greater monocyte chemotaxis and 
greater neurotoxicity (Rao et al. 2013), again supporting HIV-Tat’s role as a 
neurovirulent factor. 
Further to HIV-Tat’s neurovirulence effects, similarities between HAND and other 
dementias may also be explained by the actions of HIV-Tat. For example, HAND 
patients clinically present with molecular events very similar to those seen in Alzheimer 
disease. To illustrate, in HAND, disrupted amyloid plaque clearance may result from 
HIV-Tat’s inhibition of neprilysin (a protein responsible for clearance of amyloid 
plaques), which is also dysregulated in Alzheimer disease (Achim et al. 2011; Rempel & 
Pulliam 2005). Therefore, despite different aetiologies, at least some similar molecular 
processes appear to underlie both types of dementia. Indeed, transcriptome analysis 
reveals an overlap between gene expression networks in brain tissue samples from 
Alzheimer disease and HAND patients and proteome analysis reveals an overlap in 
differential expressed proteins in a similar comparison of these dementias (Levine et al. 
2013; Zhou et al. 2010; Rempel & Pulliam 2005). Given HIV-Tat’s contribution to 
neurovirulence, this protein may at least in part explain these similarities. While a 
detailed comparison of the molecular events underlying distinct dementias is beyond the 
scope of this thesis, the evidence does suggest that HIV-Tat exposure is important in 
dementia progression during HAND. 
Regarding what is known about HIV-Tat’s mechanism of neurodegenerative 
action, it causes N-methyl-D-aspartate receptor (NMDAR)-mediated apoptosis, as well 
as post-synaptic density loss in vitro by binding to low density lipoprotein (LDL) 
receptor-like protein (Eugenin et al. 2007; King et al. 2010; Kim et al. 2008). While this 
information might be important in the development of targeted HAND therapies, given 
that synaptodendritic injury is a better correlate of HAND than frank neuronal loss, and 
is believed to be a reversible process (Ellis et al. 2007; Everall et al. 1999; Bellizzi et al. 
2005), it is perhaps more beneficial to focus on HIV-mediated synaptic damage (rather 




strategies. Indeed, HIV-Tat exposure is linked to impaired learning and memory - 
processes known to involve synaptic dynamics (Goellner & Aberle 2012) - as well as 
grey matter deficits in mice (Carey et al. 2012; Carey et al. 2013). These observations 
point to HIV-Tat’s direct involvement in the HAND phenotype and suggest a functional 
consequence of HIV-Tat exposure. Elucidation of the molecular correlates of synaptic 
damage is therefore important for a better understanding of HAND pathogenesis. While 
other HIV proteins, such as HIV viral protein R (HIV-Vpr), can negatively affect 
neuronal physiology, HIV-Tat seems particularly important as it is the only HIV protein 
actively secreted by infected primary immune cells in the CNS, suggesting that the local 
CNS concentration of HIV-Tat may be relatively high (Na et al. 2011; Nath 2002; Perry 









Figure 2. Linear representation of HIV-Tat’s structural domains a Domains of HIV-Tat. Exon 1 
contains all known functional regions of HIV-Tat while exon 2 is of variable length and unknown 
function (image from Tahirov et al. 2010). b Intermolecular disulphide bonds may form between 
adjacent HIV-Tat monomers causing multimerisation. Rx-SH: cysteine amino acid with SH (sulphur–
hydrogen) functional group. 
 
1.5 Cell culture models in HAND research 
Presently, most HAND research utilises rodent models of HIV infection (Carey et al. 
2012; Carey et al. 2013) or indirect studies of human cognitive functioning (e.g. via 
fMRI, Holt et al. 2012). While important insights may be gleaned from these 
approaches, the applicability of rodent findings to humans, and the sensitivity of indirect 
methods, is questionable. In the absence of in vivo human studies or readily available 
primary human CNS tissue from patients, a representative human cell culture system is 
a good practical alternative for HAND research, with the applicability and sensitivity 
required for rational prognostic marker and drug target discovery. 
While the transformed cell line SH-SY5Y (a human neuroblastoma-derived cell 














may not necessarily be representative of an otherwise healthy human CNS. However, 
progress in the field of stem cell technology has made possible more ‘realistic’ cell 
culture systems, for example in vitro maintenance of untransformed normal cells: 
human embryonic neuronal stem cells have been maintained for up to 100 passages 
without genetic immortalization, and can be differentiated to form mature human 
neuronal populations (Sun et al. 2008; Tailor et al. 2013). Such cell culture systems hold 
much promise for the study of neurological diseases, including HAND. In this current 
work, we employ such a system in determining the molecular pathology of HAND over 
time (see section 5.1 NES cell line). 
 
1.6 Mass spectrometry 
Given the lack of reliable diagnostic tests or specific treatments for conditions such as 
HAND, mass spectrometry (MS)-based discovery proteomics is a valuable technology. 
Instead of looking at only a small handful of molecules, MS ‘widens the net’ for 
putative biomarker and drug target discovery, and provides the scope and sensitivity 
necessary to quantify cell-wide changes in protein expression in response to stimuli 
(including disease state) (Walther & Mann 2010). While HAND research has made use 
of MS to identify appropriate biomarkers, few if any studies have used MS-based 
discovery proteomics to investigate cell-wide proteomic changes in neurons in response 
to HIV-derived factors (Donnelly & Ciborowski 2015; Laspiura et al. 2007; Wiederin et 
al. 2009). Indeed, although certain HIV-Tat molecular targets have been identified in 
cells, knowledge regarding global cellular changes in response to this known 
neurovirulent factor is limited, and impedes development of sensitive diagnostic tests 
and rational drug design. 
An MS instrument can be likened to a very sensitive mass scale, which is able to 
measure molecular mass, or more specifically, ion mass-to-charge ratio (m/z). From the 
characteristic m/z, one is able to infer analyte identity and quantity using software 
(discussed in more detail below). The instrument comprises three parts: an ion source to 
produce charged, gas phase ions; a mass analyser to measure the m/z of resultant ions; 
and a detector to register the number of ions at each m/z value and transmit this 
information to a data system to record the mass spectra.  
A routine MS-based discovery proteomics workflow for the measurement of 
ionised peptides (in which information from peptide ions is used to infer the presence of 
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particular proteins in a sample - ‘bottom up approach’) can be described as follows: 
total cell proteome is extracted from cell lysate and digested - typically with trypsin - to 
generate predictable peptides products. Proteins are digested before MS analysis as 
peptides ionise more easily than full proteins and sequence information is more readily 
obtained from short peptides (Duncan et al. 2010). Further, peptides are desired as they 
may be easily separated into ‘fractions’, typically by high pressure liquid 
chromatography (HPLC) based on peptide hydrophobicity (i.e. reversed-phase 
chromatography) using octadecyl bonded silica (C18) as the solid phase packing 
material. Peptide fractionation prior to MS ensures that a less complex peptide mixture 
enters the MS instrument at any given time, thereby allowing the MS instrument to 
detect as many peptide species as possible (Domon & Aebersold 2010). Ultra high 
pressure liquid chromatography (uHPLC) may be employed to increase separation 
speed, decrease sample requirement and increase both sample resolution and subsequent 
identification rates (Rodriguez-Aller 2010).  
Peptides are next ionised to facilitate their entry into, and detection by, the MS 
instrument. For complex mixtures, separation is typically done ‘on-line’ with ionisation 
in which peptides are ionised as they elute from the liquid chromatography column 
(Figure 3a). Electrospray ionisation (ESI) is the preferred ionisation method for ‘on-
line’ fractionation, as ESI requires analytes in the liquid phase. In ESI, the solution of 
peptides is sprayed in the form of charged droplets from a glass capillary under a strong 
electrical field. Once exposed to the atmosphere, the solvent evaporates and transfers 
charge to the peptides thereby creating gaseous peptide ions in a process that is not 
entirely understood (Konermann et al. 2013). An alternative to ESI is matrix assisted 
laser desorption ionisation (MALDI), in which sample is spotted onto a target plate with 
suitable light-absorbing matrix and subsequently desorbed and ionised upon laser-pulse 
excitation of the matrix (Schwamborn & Caprioli 2010).  MALDI is particularly useful 
for maintaining the spatial distribution of a sample, such as in a tissue section, as the 
entire section may be placed on the target plate (Schwamborn & Caprioli 2010). As 
mentioned, as ESI can be coupled to HPLC it is favoured over MALDI for discovery 
proteomic analysis. 
 After ionisation, peptide ions enter the mass analyser for measurement and 
detection. There are many mass analysers in use, each employing a different physical 
property of the peptide ion to determine the ion’s m/z; the most popular three are 




which ions are accelerated by an electric field of known strength. The time taken for the 
peptide ion to reach the detector at the end of a fixed length evacuated tube is measured 
and allows for the calculation of the peptide ion’s mass (Aebersold & Mann 2003). 2) 
The quadrupole mass analyser comprises four parallel metal rods surrounding a hollow 
central channel. Oscillating electric fields are applied to the rods such that only ions 
within a narrow m/z range are able to stably navigate through to the detector (Miller & 
Denton 1986; Aebersold & Mann 2003). As such, the quadrupole is often used for the 
targeted identification of molecules where the m/z is known (Miller & Denton 1986). 3) 
The Orbitrap mass analyser maintains ions in orbital motion around a central spindle 
shaped electrode and obtains a signal from the lateral motion of ions around this 
electrode within an electrostatic field (Makarov 2000). The signal is used to create a 
Fourier transformation, which is, in turn, used to determine the ion’s m/z (Makarov 
2000). The current work obtained MS data from a Q-Exactive instrument, which has an 
Orbitrap mass analyser. 
Upon detection, the data system connected to the MS instrument outputs MS1 
spectra of m/z versus intensity. The intensity of a peptide peak correlates with the 
relative amount (detection-dependent) of a particular protein in the original 
experimental sample. If a peptide ion is present at or above a certain intensity (which 
may or may not be an arbitrary user-defined value) that peptide ion may be selected and 
fragmented for a second round of MS (tandem MS a.k.a. MS2), to facilitate generation 
of fragment ion amino acid sequence information (Figure 3b) (Steen & Mann 2004).  
To elaborate how MS1 and MS2 spectra are obtained, during an MS ‘run’, MS1 
spectra are collected continuously as eluting peptides are ionised and enter the mass 
analyser. This can be visualised as a total ion chromatogram (TIC), which depicts ion 
intensity peaks over the entire MS run-time (Figure 4a). If one ‘zooms in’ at a 
particular time point in the TIC, an individual MS1 spectrum may be visualised (Figure 
4b). Multiple peptides that co-elute from the HLPC column (and that appear as a 
summed peak on the TIC) may be detected in a single MS1 spectrum - where each peak 
potentially indicates a peptide ion. Due to MS2 scan rate limitations, a subset of these 
peptide ions, for example the ‘top 10’ (highest intensity), are selected for subsequent 
fragmentation. Dynamic exclusion is also often set at a particular interval to ensure that 
peptides selected for MS2 during a full MS scan - according to their peak intensity - are 
not selected again during that interval period, thereby allowing for wide peptide 




Peptide ions selected for MS2 are fragmented to produce fragment ions by 
collision with an inert gas (e.g. Helium) in a process known as collision-induced 
dissociation (CID). Higher-energy collision dissociation (HCD) is a modified version of 
CID specific to the Orbitrap setup in which fragmentation occurs outside of the Orbitrap 
itself (Olsen et al. 2007). Peptide ions fragment most commonly at the peptide bond to 
form a series of b/y ions, from which sequence information for the peptide may be 
obtained through de novo sequencing (Figure 5) (Steen & Mann 2004). More typically 
in MS-discovery proteomic experiments, experimental MS2 spectral patterns are 
mapped to theoretical MS2 spectra generated by in silico trypsin digestion of the 
relevant proteome database (Figure 3c and Figure 4d). The identification of 
proteins/protein groups from a high throughput discovery proteomic experiment 
therefore crucially depends on the availability of a full reference proteome for the 
species being analysed. 
As the MS instrument only detects peptide and fragment ion m/z, much 
downstream computational processing is required to determine protein/protein group 
identity and quantity for the millions of peptide spectral sets generated (each set 
comprising an m/z value for the peptide ion and the associated MS2 spectrum). While 
many softwares exist, MaxQuant open-source software is routinely used by many 
laboratories to this end as it is able to reliably extract protein identity and quantity 
information from raw MS2 and MS1 spectra, respectively (Cox et al. 2009). 
Specifically, MaxQuant’s internal search engine, Andromeda, identifies protein groups 
by probability-based comparison of experimental MS2 spectra to theoretical MS2 
spectra generated by in silico trypsin digest of the reference proteome provided (Cox et 
al. 2011) (Figure 3c). Andromeda [similar to the Mascot algorithm, which is also 
probability based (Perkins et al. 1999)] assesses both peptide ion mass and the number 
and masses of MS2 fragments from the same spectral set in determining its assignments 
(Cox et al. 2011).  SEQUEST, yet another software, makes use of the same probability-
based algorithm as Andromeda and Mascot, but first filters the theoretical database, 
based on a MS1 mass tolerance defined by the experimental MS1 spectrum, before the 
theoretical spectra for comparison are generated (Eng et al. 1994).  
Due to the shear volume of spectra and the absence of certain peaks in 
experimental samples (among other factors), the possibility of obtaining false positives 
is high and must be accounted for statistically to ensure confidence in the assignment. In 




which can be interpreted as a local false discovery rate (FDR) value; the smaller the 
PEP, the more confidence that the experimental and in silico spectra did not match due 
to chance alone (Cox et al. 2011). The PEP score is calculated for a particular peptide 
identification score by comparing the number of peptide spectral matches (PSM) to a 
decoy database (comprising reverse peptide sequences) for a particular score with the 
number of PSMs to the true database for that same score (Käll et al. 2008). In addition, 
the algorithm uses peptide length, where the longer the peptide that matches the true 
database, the more likely it is that this match did not occur by chance (Cox et al. 2011). 
This is a post hoc score used to verify quality of the identification. In comparison, the 
global FDR is used to adjust stringency of the matching algorithm (e.g. Andromeda 
algorithm), again based on the number of hits to decoy and true databases (Käll et al. 
2008).  
Differences in protein quantity, between treated and control samples, are typically 
determined in relative terms. This is in contrast to the less common absolute 
quantitation where exact molecular quantities per protein are identified (e.g. AQUA) 
(Brun et al. 2007). To aid relative quantitation, samples may be labelled ahead of MS 
analysis. For example, labelling on the protein level may be achieved by stable isotope 
labelling of amino acids in cell culture (SILAC) (the gold standard), in which ‘heavy’ or 
‘light’ forms of certain essential amino acids are metabolically incorporated into treated 
and control cells, respectively (or visa versa) (Ong & Mann 2006). Treated and control 
samples are combined ahead of proteome processing and run on the MS instrument as a 
single sample. Due to the presence of heavy and light labels, one may distinguish 
between the treated and control ‘version’ of a particular protein by a discriminate mass 
difference between isotopes on the mass spectrum. Proteins may alternatively be 
labelled chemically at the peptide level by isobaric tag for relative and absolute 
quantitation (iTRAQ), in which each experimental sample is labeled with a tag of 
different composition (but same overall mass) and, upon MS2 fragmentation, unique 
reporter groups are released from the tags, which can be read in the lower m/z portion of 
the mass spectrum (Ross et al. 2004). The relative ratio of these reporter ions is 
compared to give an indication of relative abundance of a particular protein across 
experimental conditions (Ross et al. 2004).  
The ability to combine labelled treated and control conditions (as early as cell 
harvesting if SILAC is used) reduces any technical variability that may be introduced 
during proteome processing ahead of MS analysis. However, due to methodological and 
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technical advancements in MS, label free techniques - in which there is no labelling of 
proteins or peptides - are gaining popularity. Unlike labelled techniques, no additional 
(often costly) steps are required during the cell culture/proteome processing stage of 
sample preparation and there is little limit to the type and number of sample/s that may 
be analysed (e.g. certain samples, such as human tissue samples, cannot be SILAC-
labelled and both SILAC and iTRAQ are limited in the number of experimental 
conditions that may be compared due to a finite number of labels).  
Label free quantitation may be achieved by spectral count and peak intensity. In 
spectral count, the number of identified MS2 spectra (spectral count) for a particular 
protein is compared across samples with the assumption that the number of MS2 spectra 
directly correlates to protein abundance, protein sequence coverage and number of 
identified unique peptides. This method remains controversial, however, as it relies on 
counting spectra rather than measuring physical data (Bantscheff et al. 2007). In the 
peak intensity method, elution into the MS instrument of a particular peptide with a 
given m/z ratio is monitored over time to establish an elution profile. The cumulative 
area under the curve of the profile for this monoisotopic mass is then used to determine 
peptide abundance, which has been shown to correlate linearly with area under the 
curve (Bondarenko et al. 2002). MaxQuant’s label free quantitation (LFQ) value is 
calculated by a peak intensity approach. Additionally, MaxQuant’s ‘match between 
runs’ function aids peptide identification in samples with incomplete spectra for 
particular peptides. Briefly, if a peptide is identified in one sample, its identification 
information may be transferred to an unidentified spectrum in a second sample through 
matching up mass with retention time across samples (Cox et al. 2014). 
 It is important to note that a major caveat of discovery proteomics is the problem 
of protein inference; proteins can only be uniquely identified if the MS instrument 
detects a peptide that is unique to the protein. Therefore in many instances, protein 
groups, and not individual proteins, are identified. This commonly occurs, for example, 
for isoforms of a protein that differ only slightly in amino acid sequence (Nesvizhskii & 
Aebersold 2005). All members of a protein group are equally as likely to have been 
present in the experimental sample and one should be mindful of this during 
downstream biological significance analysis. To account for the possible ambiguity, 
gene name (instead of specific protein identity) is often used in order to encompass all 
the protein isoforms. 




may be performed to determine those protein groups that show significant differences in 
quantitation between treated and control conditions. For label free quantitation, the LFQ 
value may be used as the quantitation measurement for each protein group per sample. 
Tests of significance typically include 2-sampled independent t-test or analysis of 
variance (ANOVA) (if more than 2 conditions are being compared at once). These tests 
take into account the mean expression value (e.g. mean LFQ) for replicates of a 
particular protein group per condition, as well as the standard deviation of the mean, 
when determining whether a difference in the means of the treated and control 
conditions for a particular protein group is significant. Protein groups that meet a user-
defined cut-off (usually p < 0.05) are deemed significant. It is this list of significantly 
differentially expressed protein groups that is taken forward for biological significance 
analysis, such as functional classification (e.g. Panther classification, 




























































Figure 3. MS-based discovery proteomics workflow used in the current work a Total cell protein 
is digested, by trypsin, to form a peptide mixture. Peptides are separated ‘on-line’ by HLPC and are 
subsequently ionised by ESI, before entering the MS instrument for detection. For example, the 25kDa 
peptide, indicated by a yellow rectangle, acquires two positive charges during ESI to form a doubly-
charged ion (2+). b Peptide ions are detected at the MS1 level. Selected peptide ions are individually 
fragmented and detected as MS2 spectra. To continue the example of the ‘yellow peptide’, this 25kDa 
2+ peptide is detected as having a mass-to-charge (m/z) ratio of 12.5 at the MS1 level. This peptide ion 
is subsequently selected and fragmented into 6 fragments, which are detected as an MS2 spectrum, 
where each peak corresponds to one fragment (fragment ion). The MS2 spectrum is then used for 
peptide identification (see 3c). c Experimental and theoretical MS2 spectra are matched in silico by a 
software package such as MaxQuant to allow for protein identification (Figures adapted from: Duncan 
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Figure 4. Sequence and protein identification workflow for each spectrum 
identified a All peptide ions detected during a 200 minute run (i.e. TIC) at the 
MS1 (red) and MS2 (green) level for a representative experimental sample. b 
An MS1 spectrum captured at 46.214 minutes. c A single ion, corresponding to 
a single peptide, is selected for MS2. Sequence information may be extracted 
(see Figure 5). d Annotated experimental MS2 spectrum is matched to in silico 
generated theoretical spectra by Andromeda search engine in MaxQuant for 
protein identification. (Figures 4a-c obtained from current experimental work, 
Figure 4d obtained from Duncan et al. 2010). Note: at an intensity of 1.6e10, 
the TIC was higher than desired and this sample was rerun (See Results: 
optimisation of sample injection volume). This run is included here purely to 






Figure 5. Fragmentation sites along the peptide backbone The most common fragmentation site 
(upon fragmentation by the MS instrument) is the NH-C=O peptide bond, resulting in formation of a y- 
or b-ion series. The C-terminal end of the peptide is retained by y-ions. For example, y1 comprises the 
C-terminal amino acid, while y2 (a di-peptide) comprises the C-terminal amino acid as well as the
adjacent amino acid. Conversely, b-ions retain the N-terminal amino acid upon fragmentation. For
example, b6 (corresponding to y2) comprises 6 amino acids. Each amino acid has a characteristic
molecular mass. The difference in mass between y2 and y1, for example, will reveal the molecular
mass of the amino acid at the C-terminus of the peptide, thus enabling identification of this amino acid
(provided it is not modified). In this way the peptide fragment can be sequenced de novo. The b- and y-
ion series determine sequence information from opposite ends of the peptide and can be used to








The current work aimed to use MS-based discovery proteomic analysis to identify the 
cell-wide effects of full-length, exogenous, clade B HIV-Tat on non-transformed, 
differentiated human neuronal stem cells over time, representing an in vitro model of 
early HAND progression. In doing so we hoped to identify putative prognostic and 
diagnostic biomarkers and/or drug targets for improved diagnosis and treatment of 
HAND. In addition, we aimed to determine the effect of neuronal cell culture 
confluence, and (presumably) resultant synaptic density, on HIV-Tat treatment. 
Further, we aimed to characterize the neuronal properties of the in vitro cell culture 




































 Generate and analyse electrophysiology data from control neurons to establish 
whether the cell line used in this work (at the time of treatment administration) 
is representative of neurons in in vitro. 
 
 Optimise (further to Gurwitz Honours dissertation, 2013) the beta 
mercaptoethanol (BME) concentration that is able to maintain HIV-Tat in a 
monomeric state during resuspension of the protein and for long-term storage*. 
 
*NOTE: HIV-Tat readily forms multimers at high concentrations of the protein due to 
formation of disulphide bonds between cysteine rich regions of adjacent HIV-Tat monomers 
in solution (Figure 2). As HIV-Tat is required in a monomeric state for activity, HIV-Tat 
must be kept in a reducing environment (by a reducing agent, such as BME) for short- and 
long- term storage (Tosi et al. 2000).  
 
 Conduct MS-based discovery proteomic analysis, with label free quantitation, 
on lysates of cells (differentiated at ~90% cell culture confluence) exposed to 
the following conditions: HIV-Tat treatment or BME (vehicle only control), 
for 6, 24 or 48 hours.  
 
 Identify differentially expressed protein groups (from MS data), between 
treated and control conditions. Determine functional enrichment of protein 
groups that are significantly differentially expressed in order to identify 
molecular markers that become dysregulated in these cells in response to HIV-
Tat treatment over time. Analyse this information to identify putative HAND 
biomarkers and to hypothesise mechanisms of early HIV-Tat neurovirulence. 
 
 Repeat time point 2 of the time course experiment (cells harvested after 24 
hours of HIV-Tat treatment). 
 
 Repeat entire time course experiment with cells differentiated at lower cell 
culture confluence (~70%) in order to determine the effect of cell density and 












4.1 Cell culture 
Stem cells 
The cell line used in this work was a non-transformed, neuroepithelial-like stem 
(NES) cell line derived from 5-week-old (Carnegie stage 15-17) human foetal 
hindbrain, generously donated by Austin Smith’s group at the Cambridge Stem Cell 
Institute. The NES cells were maintained and differentiated as described in Tailor et 
al. (2013).  Briefly, cells were seeded at approximately 26 000 cells/cm2 on non-
pyrogenic, cell adhesion plates coated with poly-L-ornithine (0.01% w/v in phosphate 
buffered saline (PBS), Sigma Aldrich) and laminin (0.2% v/v in PBS, Sigma Aldrich) 
and incubated at 37°C, 95% humidity and 5% carbon dioxide (CO2). The NES were 
cultured in DMEM: Hams F12 medium (Sigma Aldrich) supplemented with L-
glutamine (2mM, Sigma Aldrich), penicillin/streptomycin (1% v/v, Lonza), N2 (1:100 
v/v, Invitrogen), B27 (1:1000 v/v, Invitrogen), and epidermal growth factor (EGF) 
and fibroblast growth factor 2 (FGF2) (both 0.01ng/μl, Invitrogen) (Tailor et al. 
2013).The growth medium was changed daily. For cell culture passage, cells were 
split 1:3 using tryp-LETM (Invitrogen) once a density of approximately 70 000 
cells/cm2 (~90% cell culture confluence, determined visually) was reached, which 
occurred roughly every third day.  
Differentiation 
NES cells were grown until 90% cell confluence was reached, at which point EGF 
and FGF2-containing growth medium was removed and replaced with growth 
medium lacking growth factors and containing a higher concentration of B27 (1:100 
v/v) to induce spontaneous NES differentiation (Tailor et al. 2013). The 
differentiation medium was identical to the stem cell culture medium except for the 
above-mentioned changes. Cells were washed with PBS before addition of 
differentiation medium to ensure removal of growth factors. Cell were incubated at 
37°C, 95% humidity and 5% CO2. During the differentiation process and during 
maintenance of differentiated neuronal cultures, the medium was changed twice 
weekly. 
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Visualisation of cells 
The NES were visualised using transmitted light, phase contrast setting (20x 
objective) on a Zeiss Axiovert 200M Fluorescence microscope with a Zeiss AxioCam 
high-resolution monochrome camera, and images were captured using Zeiss 
AxioVision software (version 4.8). 
4.2 Electrophysiological analysis of differentiated NES cells 
Electrophysiological studies of control NES cells, the data processing thereof, were 
carried out by Richard Burman in a collaboration with Joseph Raimondo’s 
electrophysiology laboratory (University of Cape Town). Experimental procedures 
were as follows: once day 9 post differentiation was reached, differentiated NES cells 
- attached to cell adhesion dishes - were removed from incubation and transported
rapidly and carefully to the recording chamber of a Zeiss Axioskop Upright
Microscope (Zeiss) for electrophysiological recordings.  Recordings were made in
NES cell differentiation medium (Tailor et al. 2013) at room temperature. Recordings
were only obtained during the first 2 hours following NES cell removal from the
incubator environment.
A horizontal puller (Model P-1000, Sutter) was used to pull patch pipettes (13-
20 MOhm tip resistance) from filamental borosilicate glass capillaries (2.00 mm outer 
diameter, 1.58 mm inner diameter, Hilgenberg, Germany). The pipettes were filled 
with an internal solution comprising (in mM): K-gluconate (126); KCl (4); Na 2 ATP 
(4); NaGTP (0.3); Na 2 -phosphocreatinine (10) and HEPES (10).  Osmolarity was 
adjusted to between 290 and 300 mOsM and the pH was adjusted to between 7.38 and 
7.42 with KOH.   
NES cells under electrophysiological analysis were visualised with a 40x 
water-immersion objective (Zeiss) and digital images were obtained with a charge 
couple device (CCD) camera (VX55, TILL Photonics). Recordings were made in 
current clamp and voltage clamp mode with an Axopatch 200B amplifier (Molecular 
Devices). Data acquisition was performed through an ITC-1600 board (Instrutech) 
connected to a personal computer running custom-written clamp sequences (PulseQ) 
under IGOR Pro (Wavemetrics). Analysis was performed using custom-written 
MATLAB (Mathworks) scripts. 
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4.3 HIV-Tat reconstitution and visualisation 
For long-term storage, HIV-Tat (Clade B, 86 amino acids, Diatheva) was suspended 
in 50mM BME, degassed with N2 and acidified to pH4 with trifluoroacetate (TFA, 
Sigma Aldrich), at a storage concentration of 100ng/μl HIV-Tat. For short-term 
storage, suspended HIV-Tat was buffer exchanged from 50mM BME to 10mM BME 
(final working concentration of 0.1mM BME) at 4°C using molecular weight cut-off 
(MWCO) filters (3kDa, Millipore). An assumption of no protein loss was made 
during buffer exchange and the final eluted volume was adjusted to a concentration of 
100ng/μl HIV-Tat in 10mM BME for short-term storage at -80°C.  
HIV-Tat was visualized by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) with gels comprising 5% bisacrylamide (Sigma 
Aldrich) stacking, and 15% bisacrylamide separating gels (see Table A1, Appendix 
A). Gels were run at constant 160V in a 1x tris-glycine running buffer. Dithiothreitol 
(DTT) was omitted from the sample application buffer to showcase the reduction 
ability of BME at specified concentrations. PageRuler Prestain Ladder 
(ThermoScientific, SM0671) was used on all gels. Gels were stained with Silver Stain 
(ThermoScientific) and imaged with an iPhone 5s. 
4.4 HIV-Tat treatment 
At day 9 post differentiation, differentiated NES cells were treated with a final 
working concentration of 1ng/μl HIV-Tat in 0.1mM BME. NES cells treated with 
0.1mM BME only, were used as a control. All conditions were performed in at least 
triplicate as far as possible. Samples were incubated at 37°C, 95% humidity and 5% 
CO2 for 6, 24 and 48 hours. After incubation as per experimental time point, cells 
were lifted using tryp-LE (Gibco), pelleted at 600g for 3 minutes, followed by two 
washes in PBS at 600g for 3 minutes each to remove cell debris. Supernatants were 
aspirated, cell pellets flash frozen in liquid nitrogen, and pellets subsequently stored at 
-80°C. Cell counts were performed using the Trypan blue (Sigma Aldrich) dye





4.5 Cell lysis  
Cell pellets were suspended in deionised water (dH2O) containing 1x protease 
inhibitors (Sigma Aldrich) and 1x phosphatase inhibitors (PhosStop, Roche) and 
subsequently lysed with a 1x Tris/HCl pH7.6 radioimmunoprecipitation assay (RIPA) 
buffer (adapted from Holden & Horton 2009 buffer 4 - see Appendix A)  excluding 
10mM DTT, which interferes with bicinchoninic acid (BCA) quantitation (Pierce
TM 
BCA Protein Assay Kit instructions). Cell lysates were each incubated on a rotor for 1 
hour at 4°C with 1μl Benzonase nuclease ultrapure (Sigma Aldrich). Cell lysates were 
finally centrifuged at 14 000g for 10 minutes. Supernatants, containing the cell 
protein content, were transferred to new 1.5ml flip top tubes. 
 
4.6 Sample preparation for MS analysis - protein quantitation, digestion and 
cleanup 
Protein quantitation, digestion and cleanup were performed in parallel for all samples. 
PierceTM
 
BCA Protein Assay Kit microplate procedure (ThermoScientific) was 
utelised for protein quantitation with Bovine Serum Albumin (BSA) as a standard. 
Absorbance values were read at 560nm with Biorad iMarkTM
 
microplate reader, 
including path correction for sample volume. BSA standard curves were generated 
using Microplate Manager software (version 6.1). Total protein present in each 
sample was then reduced with 100mM DTT for 30 minutes at room temperature. 
Peptides for MS analysis were generated on 30kDa MWCO filters (Millipore) 
using the filter-aided sample preparation (FASP) protocol developed by Matthias 
Mann’s group (Wiśniewski et al. 2009). Briefly: samples were mixed with 8M urea (a 
non-detergent chaotrope) in tris/HCl pH8.5 in order to remove low molecular weight 
compounds, present in the lysis buffer (e.g. SDS), that would interfere with 
downstream MS if not removed (essentially a buffer exchange step); thiol groups 
were carboamidomethylated by 0.5M iodoacetamide to prevent intra- and inter- 
molecular disulphide bridge formation in order to facilitate protein digestion with 
trypsin (incubation with DTT prior to FASP aids this step by reducing the thiols 
thereby making them available for carboamidomethylation); proteome was digested; 
and resultant peptides were eluted off the MWCO filters and acidified with 0.1% 
formic acid (FA) in ultrapure dH2O (both Sigma Aldrich) (Wiśniewski et al. 2009). 
An equivalent amount (30μg) of protein from each sample - as determined by BCA 
25 
quantitation - was added to each filter, respectively. Samples were incubated with 
trypsin (1:50 w/w, Promega) for 12 hours.  
Samples were desalted using reverse-phase C18 chromatography (C18 columns 
manufactured in-house from C18 discs, Millipore) in preparation for MS analysis. 
C18 columns were equilibrated with 80% MS grade acetonitrile (ACN, Sigma 
Aldrich) acidified with 0.1% FA. 10μg peptide from each sample was desalted on 
separate C18 columns - one column per sample - by the addition of 2% ACN acidified 
with 0.1% FA. Finally, peptides were eluted with 60% ACN acidified with 0.1 % FA. 
Desalted peptides were dried at room temperature using a SpeedyVac (Savant) and 
resuspended in 0.1% FA (Sigma Aldrich) in ultrapure dH2O to a final concentration 
of 250ng/μl (500ng/μl for the 24-hour repeat experiment), which was estimated from 
BCA quantitation, at the protein level, on the assumption of no protein loss during 
FASP.
4.7 Liquid chromatography-MS analysis parameters 
Liquid chromatography tandem MS (LC-MS2) analysis was performed on a Q 
Exactive MS instrument coupled to a Dionex uHPLC (R53500nano) (both Thermo 
Fischer Scientific). For label free quantitation, samples were run individually. Sample 
volumes for injection were optimized batch-wise. For the 24-hour repeat experiment, 
5μl of 0.5μg/μl per sample was injected. Samples were monitored throughout data 
collection to ensure machine and column stability as well as desired raw data quality. 
All samples, for all experiments, were injected into the sample loop at a flow rate of 
3μl/min in 2% buffer B (0.1%FA/ACN) and 98% buffer A (0.1% FA/dH2O). Samples 
were then loaded onto a 50cm, 75μm diameter, C18 reverse phase analytical column 
(3.6μm Aeris C18 packing material, packed in house, Separations) and subsequently 
eluted during a 150-minute segmented gradient (4-30% buffer B) at a flow rate of 
300nl/min. Eluents were ionised by ESI (~ 2.5kV) before entering the mass analyser. 
At the end of each sample run, a 30-minute wash cycle was run. The wash comprised 
a segmented gradient (5-55% buffer B, and final 10 minutes at 80% buffer B). Every 
four samples, a longer wash (80 minutes) was run.  
Mass spectra were collected with settings essentially as those described by 
(Pirmoradian et al. 2013) with the following amendments: scan range was set at 300-




MS2 spectra with 70 000 resolution at MS1 level; and dynamic exclusion was set at 
30 seconds (s). Elaborated scan parameters may be viewed in Table 1. Ion 
fragmentation was performed using the HCD method. 
 
Table 1 Mass spectrometry scan parameters 
MS level Parameter Setting 
MS1 Run time 10-145 minutes 
 Polarity positive 
 Default charge state 2 
 Scan range 300-1750 m/z 
 Resolution 70000 
 Automatic gain control 
target 
3e6 
 Maximum injection time 250ms 
MS2 Resolution 17500 
 Automatic gain control 
target 
5e4 
 Maximum injection time 80ms 
 TopN 10 
 Isolation window 2 m/z 
 Scan range 200-2000 m/z 
 Intensity threshold 6.3e3 
 Dynamic exclusion 30s 
 
 
4.8 Data analysis  
Raw mass spectra were processed for peptide peak identification and quantitation by 
MaxQuant software (version 1.5.03) (Cox et al. 2009). Default MaxQuant settings 
were used with the following modifications: labeling was set to singlet; LFQ was 
selected for relative label free quantitation; ‘match between runs’ was selected to 
increase the probability of identifying protein groups in all samples and to aid in the 
comparison of protein group quantities across samples; and only peptides unique to a 
protein group were used for quantitation. MaxQuant’s inbuilt search engine, 
Andromeda, was used for protein group identification using the UniProt Human 
proteome database as the reference (FASTA, downloaded on 12/01/15) (Cox et al. 
2011). In addition, MS2 spectra were compared to a decoy database, comprising 
reverse sequences of each protein, in order to statistically account for false positives.  




that mapped to a sequence in the decoy database or that mapped to a known 
contaminant. In addition, only protein groups that had an LFQ measurement in each 
experimental sample, and had a satisfactory PEP score (< 0.01), were taken forward 
for downstream data analyses.  
MS data quality and summary statistics were assessed with the aid of a script 
developed by Karsten Krug (Proteome Center Tuebingen, University of Tuebingen, 
Germany) in the R environment for statistical computing. Further data analysis was 
performed using R scripts developed in-house, for which LFQ values were used as a 
relative measure of protein group expression. Scatterplots and boxplots of protein 
group expression values were performed to establish technical variability within 
replicates and variability across experimental conditions. Hierarchical cluster 
analysis, using a Euclidean model of absolute distance, was performed in order to 
determine whether samples in a particular treatment group had similar protein 
expression profiles. Protein expression profiles were visualised using heat maps, in 
which the darker the banding pattern, the greater the expression of that particular 
protein. Differential expression analysis was performed by hypothesis testing, using 
the independent two-sampled t-test (p < 0.05) for each protein group (HIV-Tat treated 
versus control), in order to identify differentially expressed protein groups. 
Hypothesis testing results were visualised by volcano plot. 
 
4.9 Biological significance analyses  
Functional classification analysis and gene annotation were performed using Panther 
(www.pantherdb.org; Mi et al. 2013; Mi et al. 2013(1)) and GeneCards 
(www.genecards.org), respectively, in order to determine the biological meaning of 
the data. Gene names, corresponding to differentially expressed protein groups (from 
the comparison of HIV-Tat treated versus control conditions) were used for the 
analyses. Gene names, and not protein groups, were used in order to reduce false hits 
due to the ‘protein groups problem’ (Nesvizhskii & Aebersold 2005).  
 In Panther Gene List Analysis, the following parameters were selected: 1. ‘ID 
list’ selected as list type, 2. Species set to Homo sapiens, and 3. functional 
classification viewed on bar chart. The Panther interface allows one to view bar charts 
of Panther protein class ontologies at progressively lower Panther protein class terms, 




recreated, at various hierarchical levels, as line graphs in R (using scripts developed 
in-house) in order to visualize the change in number of genes that map to a particular 
Panther classification over time. Each bar chart, per time point, was also viewed as a 
table of genes (from the input list of differentially expressed protein groups) that 
mapped to that particular Panther protein class. GeneCards was then consulted to 
functionally annotate the genes belonging to each grouping. Gene function was 
correlated to log2 fold change (HIV-Tat/ control) in order to gain insight as to the 
effect of HIV-Tat treatment on the neuronal proteome.  
Further, statistical over-representation analysis (version 10.0, released 15/05/15) 
of Panther protein classes per time point was carried out - using the online Panther 
tool - in order to determine the Panther protein classes significantly over/under 
represented when compared to the background. The following parameters were user-
specified: organism set to H. sapiens; list of differentially expressed genes, per time 
point, was used as the ‘analysed list’; full list of genes identified, per time point, was 






5. Results  
 
5.1 NES cell line 
NES, the cell line used in this work, was derived from 5-week-old (Carnegie stage 15-
17) human foetal hindbrain (Tailor et al. 2013). NES cells grew as a monolayer and 
formed characteristic rosette-like groupings (Figure 6a) as has been previously 
characterised (Tailor et al. 2013). The cells spontaneously differentiated when growth 
factors, EGF and FGF2, were removed from the growth medium, and after 9 days 
there were drastic changes to cell morphology, such as decreased cell body size and 
extensive neuronal network formation (Figure 6b). As the cells closely responded to 
growth cues from the medium (e.g. the removal of growth factors), the assumption 
that these cells are not genetically immortalized was supported. As such, these non-
transformed, differentiated cells cell were preferred over the transformed, 
neuroblastoma-derived SH-SY5Y cell line routinely used in cell culture models of 
HAND (Cartier et al. 2003). All HIV-Tat treatments were administered at 9 days post 
differentiation. 
 








5.2 Electrophysiology of differentiated NES cells 
Patch-clamp recordings were carried out in a collaboration with Richard Burman from 
Dr Joseph Raimondo’s electrophysiology group (UCT) in pilot study of 10 
differentiated, control NES cells (pooled from two experimental sittings) at day 9-post 
differentiation - the time point at which all HIV-Tat treatments were administered. 
Electrophysiology data of control NES cells were collected in order to confirm that 
the cell culture system used in this work had electrical features expected of neuronal 
tissue. NES cells were targeted for whole-cell recordings based on their 
morphological properties, namely: a small round or ovoid cell body with diameter 
between 5-10μm and the presence of two or more extended processes (Figure 7a).  
Following the attainment of a whole-cell patch, current-clamp was used with the 
application of current pulses of between 0 and 10 pico amps (pA) (Figure 7b).  Most 
cells responded to the injection of current and were capable of generating single 
spiking activity action potentials (Figure 7b), an indication of neuronal maturity 
(Moody & Bosma 2005). Due to the electrochemical nature of action potential 
generation, the response of differentiated NES cells to electrical stimulation indicated 
the presence of voltage-gated ion channels (Hodgkin et al. 1951). Specifically, flow of 
current through voltage-gated sodium (Na+) and voltage-gated potassium (K+) 
channels were determined in voltage-clamp mode (Figure 7d and c).  To achieve this, 
NES cells were clamped at 60 milli volts (mV) and then at increasing mV in 20mV 
steps to elicit a voltage-gated response from both voltage-gated Na+ and K+ channels.  
The maximum current (I) transferred through these channels was then measured with 
the average maximum INa+ and IK+ currents being 249.58 ± 166.91 pA and 181.56 ± 
128.18 pA, respectively.  These INa+ and IK+ values are lower than what has been 
observed in previous studies (Telias et al. 2014; Song et al. 2013). 
Furthermore, average resting membrane voltage (Vm) was determined to be -
55.83 ± 17.71mV (Figure 7e), which is similar to what has previously been observed 
in human-induced-pluripotent-stem-cell-derived neurons (Song et al. 2013). The 
average input resistance (IR) - reflective of ion channel expression - was then 
determined to be 3853.98 ± 2406.30mΩ  (Figure 7f), which is slightly higher than 





The abovementioned findings suggest that the current cell line - in its 
differentiated state - is broadly similar to the functional neuronal characteristics seen 
in other stem-cell-derived neuronal lines. It was in this differentiated state that NES 


































Figure 7. Differentiated NES cells displayed neuronal characteristics at day 9-post 
differentiation, as indicated by whole-cell patch-clamp a Differentiated NES cells were selected for 
electrophysiological study based on cell size (5-10μm in diameter) and the presence of two or more 
extended processes. The red line in this image outlines the micropipette and allows for easy 
identification of the specific cell recorded in current clamp mode (See Figure 7b). b Current clamp 
analysis. Current was injected in increasing steps of 10pA, for 0.8 seconds at a time, resulting in 
changes to neuronal membrane potential (Vm). Each trace in the upper graph (mV versus time) 
corresponds to a particular current clamp (pA vs time). A set of corresponding traces from the upper 
and lower graphs is highlighted to illustrate this coupling. c and d Voltage clamp analysis measuring 
current flowing through voltage-gated potassium (K+) channels and voltage-gated sodium (Na+) 
channels, respectively. Voltage (in mV) was injected in increasing steps of 20mV for 0.8 seconds at a 
time, resulting in opening of Na+ channels (Figure 7d is an enlargement of the first few milliseconds of 
the trace in Figure 7c) and later opening of K+ channels (Figure 7c), which corresponded to changes in 
flow of current across the cell membrane (measured in pA). The synchronised opening of these 
voltage-gated ion channels resulted in an action potential (Hodgkin et al. 1951). e Resting membrane 





5.3 HIV-Tat reconstitution and visualisation 
Since HIV-Tat is only active in its monomeric form (Tosi et al. 2000), a reducing 
agent concentration must be established which both maintains HIV-Tat in a 
monomeric state and is low enough not to affect cell viability. During previous 
optimisation of parameters pertaining to HIV-Tat resuspension and buffer exchange, a 
working concentration of 0.1mM BME was found to meet these criteria (Gurwitz 
Honours dissertation, 2013). BME at this concentration is in fact often used in cell 
culture media as a redox scavenger (Danovi et al. 2012).  
The current work additionally found that filtered HIV-Tat remained monomeric 
during long-term storage (≥ 18 months at -80°C) (Figure 8 lanes 6 and 7) as well as at 
initial resuspension concentrations of BME as low as 50mM (Figure 8 lane 3), and 
can be stored at BME concentrations as low as 10mM (Figure 8 lane 4). While there 
was some evidence of filtered HIV-Tat dimerising after 15 months at -80°C (Figure 8 
lane 6), this band was very faint indicating little protein in this conformation. In 
addition, the current work found that the filtering flow-through contained no protein 
(Silver Stain lower detection limit - 0.25ng) (Figure 9, lane 6 & 7), suggesting that 
the filtering method - required to achieve a BME treatment concentration of 10mM 
from a storage concentration of 50mM BME - was robust. 
The following observation from SDS-PAGE analysis must be noted: the HIV-
Tat isoform used here was an 86 amino acid, 9kDa protein, but it consistently 
migrated to a gel position corresponding to 12kDa (Figures 8 and 9). Given that the 
HIV-Tat suspension was pure (as per Diatheva quality control), this observation was 
interpreted as an effect of SDS-PAGE analysis - for example due to an 
uncharacteristic binding ratio of SDS (Rath et al. 2009) - as opposed to an effect 






Figure 8. Filtered HIV-Tat was monomeric at a low starting BME concentration (50mM), across 
filters and over time (lanes from left to right) Lane 1 molecular weight (Mw) marker. Lane 2 blank. 
Lane 3 HIV-Tat suspended in 50mM BME (100ng/μl, 400ng). Lane 4 filtered (from 50mM) HIV-Tat 
in 10mM BME (100ng/μl, 400ng). Lane 5 blank. Lane 6 filtered (from 350mM) HIV-Tat in 10mM 
BME, at -80°C for 15 months  (100ng/μl, 400ng). Lane 7 HIV-Tat suspended in 350mM BME, at -




















































































































Figure 9. HIV-Tat was undetectable in filtrate flow through (lanes from left to right) Lane 1 
molecular weight (Mw) marker. Lane 2 blank. Lane 3 HIV-Tat suspended in 50mM BME (100ng/ μl, 
400ng). Lane 4 filtered (from 50mM) HIV-Tat in 10mM BME (100ng/ μl, 400ng). Lane 5 filtered 
(from 50mM) HIV-Tat in 10mM BME, stored at -80°C for 1 month  (100ng/ μl, 400ng). Lane 6 HIV-
Tat flow through from filtrate in lane 4. Lane 7 HIV-Tat flow through from filtrate in lane 5. Lane 8 











































































































5.4 Time course experiment with NES cells differentiated at 90% cell confluence 
5.4.1 Experimental layout 
Once 90% cell confluence was reached, NES cells were differentiated1. At day 9 post-
differentiation, cells were treated with 1ng/μl HIV-Tat in 0.1mM BME, and harvested 
at 6, 24, and 48 hours post-treatment as an in vitro model of HIV infection in the CNS 
over time. This concentration of HIV-Tat has been widely used in cell culture models 
of HAND and approximates the concentration of HIV-Tat in the CNS of HAND 
patients (Xiao et al. 2000; Perry et al. 2010). Cells appeared unchanged after 
treatment and no sign of apoptosis was observed (visually determined, data not 
shown).  
 HIV-Tat concentration for treatment was selected based on literature and 
previous work. Day 9 post differentiation was selected as time point 0, as the 
proteome of differentiating NES cells stabilizes between 8 and 12 days post 
differentiation (Garnett, unpublished), and NES cells produce action potentials at this 
time indicating that they display neuronal tissue characteristics (see above section). 
Selection of time points for the time course experiments (Figures 10 and 30) was 
based on literature and previous work. For example, in response to HIV-Tat 
treatment, a large calcium influx has been reported for up to 8 hours after treatment, 
followed by cessation of this effect (Krogh et al. 2014). Therefore, the 6-hour time 
point was chosen in an attempt to identify maximal proteomic signatures that may 
support this finding. The 24-hour time point was chosen to serve as a technical repeat 
of previous work (Gurwitz Honours dissertation, 2013). The 48-hour time point was 
selected in order to observe whether the effect of a once-off HIV-Tat dose on gene 
expression would be sustained over a period of time longer than 24 hours.  
 The experimental design can be viewed in Figure 10. Samples compromised 
during processing (e.g. culture de-attachment, data not shown) were excluded from 
analysis, as indicated by dashed out circles in Figure 10. Samples were named 
according to; cell confluence level, harvesting time point, culture condition, and 
biological replicate number. A sample identifier key can be viewed in Figure 11.   
 
                                                        
1 Differentiation at 90% cell confluence is specified in order to separate this time course experiment 
from a second experiment specified later in this work, in which this time course experiment was 
repeated with cells grown to 70% cell confluence and then differentiated. 
 
37 
Figure 10. Time course experimental design T1: Time point 1 (harvested at 6 hours post-treatment), 
T2: Time point 2 (harvested at 24 hours post-treatment), T3: Time point 3 (harvested at 48 hours post-
treatment). One circle represents one biological sample (cell culture dish). TAT: HIV-Tat treated 
samples. BME: control samples. Dashed out circles indicate that the sample was compromised (data 
not shown) and as the result excluded from final analyses.  
Figure 11. Sample identifier key In this example: sample from time point 1, control sample (BME), 
and biological replicate 1. The letter ‘H’ preceding the time point (e.g. HT1) is the dataset identifier for 
cells differentiated at 90% cell confluence.  
5.4.2 Sample preparation for MS analysis 
Cell counts were determined from harvested, PBS-washed cell pellets of HIV-Tat 
treated and control cells. Protein quantitation per sample was then determined by 
BCA quantitation of lysed cell pellets. Cell count and protein-level BCA quantitation 
correlated well across samples (Table 2; raw BCA quantitation data not shown). In 
addition, amount of protein recovered per cell was largely in agreement across 
experimental conditions (average cell count: 2.77 x 106 ± 0.55 x 106, average protein 
yield per cell (in pg): 60.91±17.37). Interestingly, for HT2_BME samples, the protein 
yield per cell was a bit higher than the rest of the samples across time points, despite 
similar cell counts across all samples. However, further data quality control measures 
showed no systematic variation in proteome composition for these samples (see 
section 5.4.4 Data Analysis). Protein quantitation facilitated carrying forward the 
HT1_BME1 
Time point 1 
Vehicle only control, 













same amount of protein from each sample (30μg) - as required by label-free MS 
experiments - for proteome processing by FASP upstream of MS analysis. 
 
Table 2 Cell counts and protein quantitation for time course experiment of cells grown to 
90% cell confluence and differentiated 







recovered (g)  
 
Protein yield 
per cell (in pg) 
HT1_BME1 3.07 2.33 147.48 48.03 
HT1_BME2 2.48 2.60 173.32 69.88 
HT1_BME3 3.050 2.48 170.62 55.94 
HT1_BME4 3.51 2.15 138.48 39.44 
HT1_TAT1 2.50 2.55 144.05 57.62 
HT1_TAT2 2.39 1.77 137.65 57.59 
HT1_TAT3 3.34 2.11 137.87 41.27 
HT2_BME1 2.69 2.93 217.99 81.04 
HT2_BME2 2.11 3.045 206.15 97.70 
HT2_BME4 2.11 2.87 203.70 96.54 
HT2_TAT1 2.15 1.56 110.56 51.42 
HT2_TAT3 3.58 2.61 185.21 51.73 
HT2_TAT4 3.73 2.19 157.76 42.29 
HT3_BME1 2.29 2.14 156.49 68.34 
HT3_BME2 2.66 2.96 213.71 80.34 
HT3_BME3 3.06 2.71 195.30 63.82 
HT3_BME4 3.46 2.42 163.49 47.25 
HT3_TAT1 2.87 2.72 183.81 64.05 
HT3_TAT2 1.90 1.89 119.64 62.97 
HT3_TAT3 2.48 1.43 101.32 40.85 
* See Figure 11 sample identifier key; TAT: HIV-Tat treated; BME: control samples. 
** Cell counts from 6cm cell culture dishes 
 
5.4.3 LC-MS analysis parameters - optimisation of sample injection volume 
While BCA quantitation provided a good protein estimate prior to proteome 
processing, potential protein loss during processing also had to be accounted for. This 
was achieved by optimising the volume of sample that was loaded onto the LC-MS 
instruments, which both facilitated loading of similar amounts of peptide across 
samples, and prevented peptide over-loading, which may have resulted in HPLC 




of a 250ng/μl sample) was loaded onto the reverse phase C18 column and the TIC 
intensity was noted (Figure 12c). A maximum intensity of 5.5e9 at the MS level was 
the benchmark, as this was high enough so as to increase dynamic range (detection of 
lower abundant peptide ion peaks), but not so high that it risked blocking the column 
and/or saturating the detector (Blackburn laboratory, unpublished). If the intensity 
was significantly below or above 5.5e9 (Figure 12c), a new injection volume - aimed 
at generating the target TIC intensity - was calculated (Figure 12d) and the sample 
was re-injected at this new volume (Figure 12e). The process was iterated until the 
target TIC intensity was achieved. 
As all samples in the current work were processed in parallel, it was assumed 
that any protein loss should be consistent across samples and therefore that the new 
volume, calculated for the first sample, could be used as the injection volume for all 
subsequent samples. Selected samples whose TIC’s still varied significantly from the 
desired intensity, were rerun at sample-specific calculated volumes (data not shown). 
Washes were included after each run (data not shown), as well as a longer wash after 
every four runs (Figure 12b) to ensure no carry over of sample and/or potential 
contaminants. As can be seen in Figure 12b - an example of a wash - the contaminant 
peak at 51 minutes eluted as a single defined peak, strongly suggesting that the wash 
removed this contaminant from the column. Further, the column was unchanged by 
the previous presence of the contaminant, as suggested by the reference sample TIC 
(Figure 12a) and spray stability (Figure 12).  
The initial liquid chromatography gradient gave good separation of peptides, as 



































Figure 12. Optimisation of sample injection volume for MS runs a Reference. b Wash. c 
Overloading of experimental sample (i.e. too much protein). d Equation to calculate new volume of 
peptide sample to be injected to obtain desired TIC peak intensity (5.5e9 benchmark). e New, 
calculated amount loaded. Note: In a-c and e, trace 1 (black) shows the TIC at the MS1 level; trace 2 
(red) shows the TIC at the MS2 level. 
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 5.4.4 Data analysis 
MS data quality and raw data processing 
MS1 and MS2 data were acquired for all samples on a Q-Exactive MS instrument as 
described (see section 4.7 LC-MS analysis parameters). Figure 4 (in the 
Introduction) shows an example of TIC, MS1, MS2 and peptide sequence alignment 
data, generated for the current work by the above approach. 
Of the 1 067 211 spectra submitted to MaxQuant software for analysis, 568 656 
(53.28%) were mapped to known tryptic peptide sequences in the Uniprot Human 
protein database corresponding to an identification of 4104 protein groups in total, 
across the 20 samples analysed (FDR < 0.01), and a minimum of 2314 protein groups 
identified in each sample. The data were of good quality as indicated by a low 
percentage of contaminants (0.41% of total protein groups), a low percentage of 
matches to the decoy database (0.038% of total protein groups), and good tryptic 
digestion (few missed cleavages, as seen in Figure 13). Additionally, average 

































Figure 14. Average absolute mass error of the MS instrument per run ppm – parts per million, 























































































































Descriptive statistical analysis 
Technical replicates of proteome-wide quantitation correlated well (R2 > 0.95 for all 
comparisons; Figure 15) and there was no systematic technical variation across 
experimental conditions or across time points (Figure 16). For all time points (Figure 
17a-c), HIV-Tat and control samples clustered separately, but this clustering was not 
very strong. Subtle changes to smaller protein sub-groups (representing significantly 
differentially expressed protein groups) were revealed by hypothesis testing (see next 
section: Differential expression analysis). Additionally, there was evidence of weak 
clustering by time point when all samples across time points were analysed together 
(Figure 17d). However, as each treated group was only compared to the control 
group from that time point (i.e. HIV-Tat treated from time point 1 versus control from 
time point 1 etc.), these effects should not bias downstream analyses. 
Figure 15. Agreement between technical replicates and across experimental conditions for all three time 
points log2LFQ protein expression values from each experimental sample were plotted against those from 
every other experimental sample, per time point (log2 of values used for visualisation purposes). a HT1: 6 
hours post-treatment. b HT2: 24 hours post-treatment. c HT3: 48 hours post-treatment. Numeric values in the 
top right half of each graph indicate the R2 value for each comparison. TAT - HIV-Tat treated, BME - control. 

























Figure 16. Boxplot representations of log2LFQ intensity values per replicate per condition per 







Figure 17. Hierarchical cluster analysis of total proteomic profile (using log2LFQ values) 
revealed weak clustering of experimental conditions a HT1: 6 hours post-treatment. b HT2: 24 
hours post-treatment. c HT3: 48 hours post treatment. d all time points included. Note: the darker the 
band, the greater the expression of that particular protein group. TAT - HIV-Tat treated, BME - 







































































































































































Differential expression analysis 
 
Protein groups expressed differentially between HIV-Tat and control samples per 
time point - as determined by hypothesis testing - were represented as a volcano plot 
(Figure 18). Upon visual inspection of the volcano plots, it was apparent that the 
magnitude of differential expression was subtle (Figure 18, -1 < log2FC < 1). While 
only subtle differences in log2 fold change were expected, as most of the proteome 
does stay the same in any experiment-control comparison, differences were 
statistically significant for many protein groups as judged by t test analysis (Figure 
18, p < 0.05; Table 3). The top five most up-regulated and top 5 most down-regulated 
protein groups, per time point, can be viewed in Tables 4-6.  
Differentially expressed protein groups may be further analysed to determine 
the temporal changes in protein expression - as well as the significance of such 
changes - in response to HIV-Tat treatment, since they relate to HIV-Tat’s effect on 
neurons in cell culture in our in vitro model of HIV infection of the CNS (see next 
section: Biological significance analysis). 
 
 
Figure 18. Visual representation of expression changes between HIV-Tat and BME (vehicle-only) 
treated samples protein groups plotted as a function of significance (-log10 p value) and log2 fold 
change (log2FC). a HT1: 6 hours post treatment. b HT2: 24 hours post treatment. c HT3: 48 hours post 
treatment. Fold change = TAT/BME. Horizontal line indicates p = 0.05 (level of significance set for the 
independent t-test analysis per protein group). Vertical lines indicate two fold change in expression 
(±log21). Up-regulated protein groups are coloured green, down-regulated protein groups are coloured 










Table 3 Number of genes (gene acting as proxy for ‘protein groups’) identified at each time 











Table 4 Top 5 most up-regulated and top 5 most down-regulated protein groups at 6 hours 
post treatment 
gene.ID gene.name PEP p.value log2FC**  
EDF1 Endothelial differentiation-related factor 1 5.56e-30 0.035 0.47  
SMRC2 Isoform 2 of SWI/SNF complex subunit SMARCC2 0 0.038 0.47  
SNX27 Isoform 3 of Sorting nexin-27 9.84e-18 0.0057 0.5  
KHDR2 KH domain-containing, RNA-binding, signal 
transduction-associated protein 2 
2.53e-16 0.041 0.6  
CO3A1 Collagen alpha-1(III) 1.36e-33 0.032 0.6  
HNRPK Isoform 2 of Heterogeneous nuclear ribonucleoprotein K 0 0.026 -0.5  
PIGU Isoform 2 of Phosphatidylinositol glycan anchor 
biosynthesis class U protein 
8.91e-23 0.013 -0.57  
FYN  Tyrosine-protein kinase 3.06e-64 0.022 -0.58  
PTCD3 Pentatricopeptide repeat domain-containing protein 3, 
mitochondrial 
7.97e-46 0.043 -0.58  
E41L5  Isoform 3 of Band 4.1-like protein  1.84e-21 0.034 -0.68  

























 (p < 0.05) 
HT1 2420 131 
HT2 2669 118 
HT3 2314 45 
48 
Table 5 Top 5 most up-regulated and top 5 most down-regulated protein groups at 24 hours 
post treatment 
gene.ID gene.name PEP p.value log2FC** 
CWC15  Spliceosome-associated protein 1.11e-
05 
0.032 0.31 
LZIC Protein LZIC 4.34e-
25 
0.041 0.33 
CA123 protein C1orf123 7.64e-
41 
0.0067 0.38 
ERI3  Isoform 3 of ERI1 exoribonuclease 3 2.85e-
15 
0.00069 0.45 
G3V2L5 Ubiquinone biosynthesis monooxygenase 3.06e-
06 
0.039 0.66 
GEMI5  Gem-associated protein 5 3.96e-
23 
0.042 -0.37
UN13B Protein unc-13 homolog B 1.26e-
15 
0.021 -0.38
IGSF3 Immunoglobulin superfamily member 3 1.82e-
34 
0.0036 -0.38
NUCKS Nuclear ubiquitous casein and cyclin-dependent 







**FC - fold change, HIV-Tat/control 
Table 6 Top 5 most up-regulated and top 5 most down-regulated protein groups at 48 hours 
post treatment 
gene.ID gene.name PEP p.value log2FC*
* 
SNX27 Isoform 3 of Sorting nexin-27 9.84e-
18 
0.042 0.47 
BRE1B E3 ubiquitin-protein ligase 2.43e-
43 
0.029 0.49 
PHF5A PHD finger-like domain-containing protein 5A 4.22e-
45 
0.037 0.49 
M0QXF7 protein C19orf10 (Fragment) 2.67e-
15 
0.036 0.50 
RUXF Small nuclear ribonucleoprotein F 2.18e-
80 
0.043 0.53 
GALE UDP-glucose 4-epimerase 3.48e-
24 
0.021 -0.38





S4R456 40S ribosomal protein S15 (Fragment) 5.51e-
61 
0.030 -0.47
STK39 Isoform 2 of STE20/SPS1-related proline-













5.4.5 Biological significance analysis  
Functional classification of protein groups significantly differentially expressed 
between time points - in accordance with Panther protein class (Mi et al. 2013) - 
revealed those biological functions affected by HIV-Tat treatment over time2. Trends 
observed for the absolute number of protein groups that mapped to a particular 
protein class at each time point (Figure 19a), were in agreement with trends for 
mapped protein groups normalised to the full list of protein groups identified per time 
point (Figure 19b). These trends were largely maintained when protein groups, per 
protein class, were normalised to the number of significantly differentially expressed 
protein groups per time point, except for some protein classes at time point 3 (Figure 
19a-c). This is perhaps the result of progressively fewer differentially expressed 
protein groups identified over time (Table 3, Figure 21b). 
For all figures, irrespective of normalisation method described in the above 
paragraph, the following functional classes were represented by the highest number of 
protein groups: nucleic acid binding (PC00171), hydrolase (PC00121), transferase 
(PC00220), cytoskeletal protein (PC00085), and enzyme modulator (PC00095) 
(Figure 19a-c). Perhaps most informative were nucleic acid binding (Figure 20a) 
and cytoskeletal protein (Figure 20b) classifications, as these in fact encompassed 
many members of the hydrolase, transferase and enzyme modulator classifications 
(data not shown).  Further, more specific protein classes that are functionally linked to 
these two broader protein classes (i.e. in the same Panther protein class lineage) were 
significantly over/under represented (p ≤ 0.05) when compared to the full list (i.e. 
background) using Panther’s over/under representation of protein classes tool (Tables 
7-9). Trends pertaining to nucleic acid binding and cytoskeletal protein Panther 
protein classes were therefore explored in more detail, as described below. 
 
Panther protein class: nucleic acid binding 
 
When nucleic acid binding was considered, it was apparent that there were 
proportionally fewer differentially expressed protein groups that mapped to this 
                                                        
2  Please note: when interpreting functional classification graphs (e.g. Figures 19 and 20), it is 
important observed trends over time are the effects of treatment. For example, if the trend declined, it 
did not go back to baseline/‘normal’, but rather that relatively fewer protein groups were implicated for 




classification at 24 hours post treatment, than at 6 and 48 hours post treatment 
(Figure 19c). This trend was mirrored when the proportion of protein groups that map 
to RNA binding and DNA binding (subcategories of nucleic acid binding) were 
considered (Figure 20a). In addition, most protein groups in the nucleic acid binding 
list were down-regulated at 24 hours after HIV-Tat treatment (i.e. negative log2 fold 
change), while the few that were up-regulated in response to treatment are involved in 
mRNA turnover and RNA degradation (Table B2, Appendix B). Taken together, 
these trends suggest general repression of gene expression by HIV-Tat at 24 hours 
post treatment.  
This was in contrast to what was seen at 6 hours post treatment, in which 
differentially expressed protein groups that mapped to this protein class were mostly 
up-regulated (i.e. positive log2 fold change) in response to HIV-Tat treatment (Table 
B1, Appendix B). These up-regulated protein groups are involved in chromatin 
remodelling (e.g. SMRC2) and DNA replication (e.g. MCM5 and RFA1) at the DNA 
level, as well as RNA splicing (e.g. PRP4), mRNA processing (e.g. GMPPA), and 
translational machinery (e.g. RL10, RL21, RL5, RS2) at the RNA level. This suggests 
an up-regulation of general host gene expression, by HIV-Tat, at 6 hours post 
treatment. Most nucleic acid binding protein groups were also up regulated at 48 
hours post treatment (Table B3, Appendix B), and, according to their biological 
functions, again suggest a general increase in host gene expression machinery, and 
thus host gene expression, at this time.  
 
Panther protein class: cytoskeletal protein 
 
When cytoskeletal protein was considered, more protein groups mapped to this 
classification at 24 hours post treatment than at 6 or 48 hours post treatment (Figure 
19c), thus displaying the opposite overall trend to nucleic acid binding (Figure 19c). 
Although this ‘inverted U’ trend was observed when all cytoskeletal protein groups 
were considered together, upon inspection of protein groups belonging to cytoskeletal 
protein subclasses, it was apparent that the proportion of actin related proteins 
actually increased over time (Figure 20b). As the increase in proportion was greater 
from 6 to 24 hours than from 24 to 48 hours (Figure 20b), one may tentatively 




Rather than representing cytoskeletal building block components (e.g. actin, 
microtubules and intermediary filaments), most protein groups that mapped to this 
protein class are cytoskeletal maintenance/cytoskeleton anchoring proteins (e.g. 
CTNA1 at 6 and 48 hours, which links the cytoplasmic domain of membrane 
cadherins to actin at adherens junctions) (GeneCards, www.genecards.org; Tables B4 
and B6, Appendix B) or cytoskeletal transport proteins (e.g. KLC2 and ARP10 at 24 
hours) (Table B5, Appendix B).  
In addition, when log2 fold change in expression was considered, these protein 
groups were mostly down-regulated across all three time points (Tables B4-6, 
Appendix B), while the few that were up-regulated are involved in cytoskeletal 
disassembly (e.g. DEST - at 6 hours post treatment - which is an actin depolymerising 
protein) (GeneCards; Table B4, Appendix B). This suggests that HIV-Tat treatment 
causes instability to cytoskeletal maintenance (as opposed to cytoskeletal 
dynamics/responsiveness) up to 48 hours after initial treatment, with down-regulation 









































Figure 19. Functional classifications of differentially expressed protein groups over time, 
according to Panther protein class, for the higher cell confluence experiment a absolute number of 
genes per time point. b number of genes normalised to the full list of identified genes per time point. c 
number of genes normalised to the number of differentially expressed genes per time point. Gene 
names were used as a proxy for protein groups. HT1: 6 hours post treatment, HT2: 24 hours post 














Figure 20. Sub categories per time point of Panther protein classes a nucleic acid binding b 
cytoskeletal protein. Values were normalised to the number of differentially expressed genes per time 
point. Gene names were used as a proxy for protein groups. HT1: 6 hours post treatment, HT2: 24 























Table 7 Top 10** output from over/under representation analysis (i.e. Fisher exact test results) of Panther protein class terms at 6 hours post 
treatment 
PANTHER Protein Class Background 





protein groups - 










RNA methyltransferase (PC00033) 2 2 .11 + > 5 5.52E-03 
transcription cofactor (PC00217) 24 5 1.31 + 3.81 1.05E-02 
hydrolase (PC00121) 208 5 11.37 - .44 2.44E-02 
microtubule family cytoskeletal 
protein (PC00157) 
54 0 2.95 - < 0.2 5.03E-02 
cytoskeletal protein (PC00085) 163 4 8.91 - .45 5.14E-02 
calcium-binding protein (PC00060) 53 0 2.90 - < 0.2 5.32E-02 
RNA binding protein (PC00031) 290 22 15.85 + 1.39 6.78E-02 
chromatin/chromatin-binding 
protein (PC00077) 
42 5 2.30 + 2.18 8.12E-02 
small GTPase (PC00208) 30 4 1.64 + 2.44 8.30E-02 
nucleic acid binding (PC00171) 447 31 24.43 + 1.27 8.59E-02 
* The number of protein groups belonging to background (i.e. full list) and differentially expressed protein group may not correlate with the values in Table 3 as the Panther
algorithm could not map all protein groups from the input lists
** please note that not all Panther protein classes listed are significantly over/under represented (check p.value column). However, many classes functionally linked to




Table 8 Top 10** output from over/under representation analysis (i.e. Fisher exact test results) of Panther protein class terms at 24 hours post 
treatment 
PANTHER Protein Class Background 





protein groups - 











DNA binding protein 
(PC00009) 
129 1 5.46 - < 0.2 2.47E-02 
esterase (PC00097) 19 3 .80 + 3.73 4.72E-02 
oxidoreductase (PC00176) 147 2 6.22 - .32 4.77E-02 
exoribonuclease (PC00099) 10 2 .42 + 4.73 6.75E-02 
reductase (PC00198) 58 0 2.45 - < 0.2 8.33E-02 
signaling molecule (PC00207) 53 0 2.24 - < 0.2 1.03E-01 
hydrolase (PC00121) 234 14 9.90 + 1.41 1.16E-01 
tyrosine protein kinase receptor 
(PC00233) 
3 1 .13 + > 5 1.19E-01 
phosphorylase (PC00187) 3 1 .13 + > 5 1.19E-01 
Unclassified (UNCLASSIFIED) 735 37 31.09 + 1.19 1.21E-01 
* The number of protein groups belonging to background (i.e. full list) and differentially expressed protein group may not correlate with the values in Table 3 as the Panther 
algorithm could not map all protein groups from the input lists 
** please note that not all Panther protein classes listed are significantly over/under represented (check p.value column). However, many classes functionally linked to 









Table 9 Top 10** output from over/under representation analysis (i.e. Fisher exact test results) of Panther protein class terms at 48 hours post 
treatment 
PANTHER Protein Class Background 





groups - input (out of 










cell adhesion molecule 
(PC00069) 
19 3 .37 + > 5 5.89E-
03 
extracellular matrix protein 
(PC00102) 
12 2 .23 + > 5 2.26E-
02 
extracellular matrix structural 
protein (PC00103) 
2 1 .04 + > 5 3.79E-
02 




16 2 .31 + > 5 3.82E-
02 
antibacterial response protein 
(PC00051) 
3 1 .06 + > 5 5.63E-
02 
surfactant (PC00212) 3 1 .06 + > 5 5.63E-
02 
DNA binding protein 
(PC00009) 
111 5 2.14 + 2.34 6.08E-
02 
signaling molecule (PC00207) 49 3 .95 + 3.17 6.82E-
02 
ligand-gated ion channel 
(PC00141) 
4 1 .08 + > 5 7.43E-
02 
* The number of protein groups belonging to background (i.e. full list) and differentially expressed protein group may not correlate with the values in Table 3 as the Panther 
algorithm could not map all protein groups from the input lists 
** please note that not all Panther protein classes listed are significantly over/under represented (check p.value column). However, many classes functionally linked to 




Protein groups differentially expressed at more than one time point 
 
While there was little overlap in the protein groups expressed at different time points 
post treatment (Figure 21), the few that did overlap may highlight key 
points/pathways in the progression of HIV-Tat’s effect (Tables 10-12). Particularly, 
those that were up-regulated at one time point, then down-regulated at a second time 
point - and that correlated with implicated broader biological function classifications - 
were of interest. For example, MRPL45 (involved in mitochondrial protein 
translation) (GeneCards) and DDX18 (an RNA helicase) (GeneCards) were both up-
regulated at 6 hours post HIV-Tat treatment and subsequently down-regulated at 24 
hours post treatment (Table 10). These protein groups both mapped to the protein 
class nucleic acid binding. 
Also of interest are those protein groups differentially expressed at both 6 and 
48 hours, but not 24 hours, post treatment (e.g. CO3A1, CTNA1, SNX27) (Table 12). 
These protein groups had the same ‘direction’ of expression change (log2 fold change) 
at both time points, and were therefore affected in same way at each time point (i.e. 











Figure 21. Venn diagrams showing overlap of protein groups between different time points a 
Overlap of full lists (all protein groups identified) b Overlap of lists of differentially expressed protein 
groups that meet the cut-off criteria for significance after hypothesis testing analysis, p < 0.05. HT1: 6 
hours post treatment; HT2: 24 hours post treatment; HT3: 48 hours post treatment. Venn diagrams 
generated using Venny online tool: www.stefanjol.nl/venny. 
a b 
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Table 10 Differentially expressed genes at 6 (HT1) and 24 (HT2) hours post HIV-Tat treatment 
geneID gene.name Function* log2FC** p.value PEP 




HT1: 0.23 HT1: 0.027  4.7e-07 
HT2: -0.2 HT2: 0.0032 
ACAD9 Acyl-CoA dehydrogenase 
family member 9, 
mitochondrial 
Catalyses rate limiting step 
in β oxidation 
HT1: 0.087 HT1: 0.013 2.9e-52 
HT2: -0.16 HT2: 0.025 
CSN3 COP9 signalosome complex 
subunit 3 
Protein degradation HT1: 0.15 HT1: 0.039 5.6e-18 
HT2: 0.75 HT2: 0.029 
DDX18 ATP-dependent RNA 
helicase 
RNA helicase HT1: 0.22 HT1: 0.43 8.1e-51 
HT2: -0.28 HT2: 0.029 
GSTA4 Glutathione S-transferase A4 Detoxification of lipid 
peroxidation products 
HT1: 0.16 HT1: 0.011 3.0e-36 
HT2: 0.14 HT2: 0.037 
IGSF3 Immunoglobulin superfamily 
member 3 
Cell surface receptor, 
immune system 
HT1: -0.27 HT1: 0.021 1.8e-34 
HT2: -0.38 HT2: 0.0036 
J3QRU4 Vesicle-associated membrane 
protein 2 
Docking of vesicles with 
membrane at presynaptic 
vesicle for neurotransmitter 
release 
HT1: -0.026 HT1: 0.0080 9.9e-14 
HT2: -0.27 HT2: 0.043 
PABP1 Polyadenylate-binding 
protein 1 
Translation initiation HT1: 0.098 HT1: 0.0036 0 
HT2: 0.052 HT2:  0.020 
VPS16 Vacuolar protein sorting-
associated protein 16 
Mediation of vesicle 
trafficking in endosome/ 
lysosome pathway (by 
homology) 
HT1: 0.11 HT1: 0.024 2.5e-18 
HT2: -0.24 HT2: 0.029 
* Functions from GeneCards www.genecards.org




Table 11 Differentially expressed protein groups at both 24 (HT2) and 48 (HT3) hours post treatment 






degradation of syntaxin 
1 - essential component 
of the neurotransmitter 
release machinery 
(by homology) 
HT2: -0.16 HT2: 0.015 2.43e-43 
 HT3: 0.46 HT3: 0.028 




Required for effective 
mRNA nuclear export 
HT2: -0.074 HT2: 0.0039 1.24e-91 
 HT3: 0.27 HT3: 0.023 
* Functions from GeneCards www.genecards.org 
**FC- fold change, HIV-Tat/control 
 
Table 12 Differentially expressed genes at both 6 (HT1) and 48 (HT3) hours post treatment 
geneID Gene.name Function* p.value Log2FC** PEP 
CO3A1 Collagen alpha-
1(III) chain 
Actin component HT1: 0.032 HT1: 0.58 1.3562e-33 
 HT3: 0.029 HT3: 0.44 
CTNA1 Catenin alpha-1 Actin component HT1: 0.037 HT1: -0.23 0 
 HT3: 0.030 HT3:  -0.15 
SNX27 Isoform 3 of 
Sorting nexin-27 
Endocytosis of plasma membrane 
receptors 
HT1: 0.0057 HT1: 0.49 9.8375e-18 
* Function from GeneCards www.genecards.org 
**FC- fold change, HIV-Tat/control
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5.5 Repeat of 24-hour time point 
Differentiated NES cells were treated with HIV-Tat and then harvested 24 hours after 
treatment in a repeat experiment of time point 2 (HT2) of the time course experiment. 
While the cell culture and sample preparation work for this repeat was carried out 
previously and stored at -80°C (Gurwitz Honours dissertation, 2013), MS data were 
acquired with the most up to date methods in the current work (see section 4.7 LC-
MS analysis parameters) and subsequently reprocessed in silico. All experimental 
procedures outlined in section 4 are applicable to this dataset. Outlined below are the 
experimental design, data quality parameters, descriptive statistics and differential 
expression analyses for this dataset. Further, biological significance data - as well as 
how this dataset relates to the higher confluence time course experiment - are also 
included. 
5.5.1 Experimental design 
The experimental design for this repeat experiment closely follows that of HT2 
(Figure 22, Figure 10). 
Figure 22. Experimental design T2: cells harvested 24 hours post treatment. One circle: one 
biological sample (cell culture dish). TAT - HIV-Tat treated samples. BME - control samples. Dashed 
out circles indicate that that sample was compromised during sample preparation and thus excluded 
from final analyses.  
5.5.2 MS data quality and raw data processing 
The data were of good quality as shown by high percentage of MS2 spectra identified 
(50.77%, Table 13). This corresponded to a high number of protein groups identified, 
low percentage contaminants and few spectra mapping to the decoy database (Table 
13). Further, tryptic digestion was good (Figure 23) with 87.6% total digestion. In 






Table 13 Data quality parameters for 24 hour repeat experiment 
Parameter Measurement 
MSMS spectra submitted 251285 
MSMS spectra identified 127577 (50.77%) 
Protein groups identified 3183 (1907 across all 6 
samples) 
Contaminants (%) 0.5 







































Figure 24. Average absolute mass error of the MS instrument per sample, ppm - parts per million, 
















































5.5.3 Statistical analysis 
Descriptive statistical analysis 
Scatterplots of protein expression values, for the 1907 proteins groups identified in 
each HIV-Tat treated and control sample, revealed linear relationships between 
technical replicates and across experimental conditions (Figure 25). Boxplot analysis 
(Figure 26) showed no systematic technical variation. Taken together, these results 
indicated high reproducibility. While cluster analysis showed weak clustering of 
samples by experimental condition (Figure 27), more subtle changes to protein 
expression were revealed by differential expression analysis as described in the 
following section. 
Figure 25. Agreement between technical replicates and across experimental conditions 
log2 protein expression values from each experimental sample were plotted against those from every 
other experimental sample. Numeric values in the top right section indicate the R2 value for each 





















Figure 26. Boxplot representations of log2LFQ intensity values per replicate per condition. TAT- 






















Figure 27. Hierarchical Cluster analysis of total proteomic profile revealed weak clustering of 
samples by experimental condition. Note: the darker the band, the greater the expression of that 






















































































Differential expression analysis 
 
A total of 68 protein groups were differentially expressed between HIV- Tat treated 
and control samples (p < 0.05) (Figure 28). It is this list of 68 that was taken forward 
for biological significance analyses and compared to differentially expressed protein 





















Figure 28. Visual representation of expression changes between HIV-Tat and BME (vehicle) 
treated samples protein groups plotted as a function of significance (-log10 p value) and log2 fold 
change (log2FC). Foldchange = TAT/BME. TAT- HIV-Tat treated, BME – control. Horizontal line 
indicates p = 0.05. Vertical lines indicate 2 standard deviations from 0 (±log21).  
 
5.5.4 Biological significance analysis 
The repeat correlated well with the 24-hour time point (HT2) from the time course 
experiment (Figure 29). It is apparent that both experiments contained many protein 
groups that mapped to the Panther protein classes nucleic acid binding and 
cytoskeletal protein (Figure 29). This enrichment was significant for protein classes 
related to cytoskeletal protein (p < 0.05) (Table 14), such as: class intermediate 
filament (PC00129), which was over-represented greater than 5-fold (p = 2.63e-3); 
and class extracellular matrix structural protein (PC00103), also over-represented 
greater than 5-fold (p = 3.68e-3). Further, differentially expressed protein groups that 




Tat treatment (Tables C1, Appendix C) and related to cytoskeletal 
maintenance/transport (e.g. CALD1, VINC, TAGLN). This was in agreement with 
what was seen during the time course experiment at 24 hours post treatment (Table 
B5, Appendix B).  
Nucleic acid binding class protein groups - which act at both the DNA and RNA 
level - appear to have been up-regulated in response to HIV-Tat treatment (Table C2, 
Appendix C). This finding was surprising as it is in opposition to the trend seen at 
HT2, in which nucleic acid binding protein groups are down-regulated (Table B2, 
Appendix B). The protein class nucleic acid binding - or other Panther protein classes 
in the same parent lineage - was/were not significantly over/under represented in this 
repeat experiment (Table 14). 
 
 
Figure 29. Panther protein class classification for repeated 24 hour time point data correlated 
with time point two from the time course experiment (HT2) a 24 hour time point for time course 








Table 14 Top 10 output from over/under representation analysis of Panther protein class 










groups - input 






































































5.6 Time course experiment with NES cells differentiated at 70% cell confluence 
The above time course experiment (cultured cells differentiated at 90% cell 
confluence and then treated at 9 days post differentiation) was repeated with cells 
differentiated at lower cell confluence (70%) in order to determine the effect of cell 
density - and (presumably) resultant synaptic density - on HIV-Tat treatment. All 
Experimental Procedures pertaining to cell culture (except confluence at 
differentiation), HIV-Tat treatment, and MS runs and data processing applied to this 













Figure 30. Lower cell confluence (70%) time course experimental design T1: Time point 1 
(harvested 6 hours post treatment). T2: Time point 2 (harvested 24 hours post treatment). T3: Time 
point 3 (harvested 48 hours post treatment). One circle represents one biological sample (cell culture 
dish). TAT: HIV-Tat treated samples. BME: control samples. Samples with dash through indicate that 
that sample was compromised (data not shown) and thus excluded for final analyses. Note: T2TAT1 
and T2TAT3 were run twice each on the MS instrument and only protein groups common to both runs 
in each case were taken forward for analysis. This was done in order to account for the shortfall of only 











Figure 31. Sample identifier key In this example: sample from time point 1, control sample (BME), 














Time point 1  





5.6.1 MS data quality and raw data processing 
 
Table 15 details MS data quality parameters from this dataset, which were of good 
quality as was evident from good percentage MSMS spectra identified, large number 
of protein groups identified as well as low contaminants and mappings to the decoy 
database. Further, tryptic digestion was good (Figure 32), despite being a bit lower 
than the expected 80% total digestion (Blackburn laboratory, unpublished). In 
addition, low average absolute mass error was evident (0.7 ± 1 ppm, Figure 33). 
 
Table 15 Data quality parameters for lower cell confluence  
experiment 
Parameter Measurement 
MSMS spectra submitted 1144021 
MSMS spectra identified 455737 (39.84%) 
Protein groups identified 3692 
Contaminants (%) 0.406 




















Figure 33. Average absolute mass error of the MS instrument per run ppm - parts per million, 
BME  - control, TAT - HIV-Tat treated. 
 
5.6.2 Statistical analysis 
Descriptive statistical analysis 
 
Technical replicates correlated well (R2 > 0.9 in all comparisons, Figure 34) - except 
T2TAT2, which was removed from further analyses (T2TAT1 and T2TAT3 were run 
twice each and the average taken to account for the loss of T2TAT2). In addition, 
boxplot analysis (Figure 35) showed no systematic technical variation, indicating 
high reproducibility. Within each time point, treated and control samples did not 
appear to cluster separately (Figure 36a-c). Moreover, when all time points were 
analysed together by cluster analysis, they did not cluster by time point either (Figure 
36d) - apart from a few cases of clustering within biological replicates within time 
points - which suggests that no exogenous time point biases were introduced. More 






















































































































Figure 34. Agreement between technical replicates and across experimental conditions for all 
three time points log2 protein expression values from each experimental sample were plotted against 
those from every other experimental sample, per time point. Numeric values in the top right half of 



























Figure 35. Boxplot representations of log2LFQ intensity values per replicate per condition per 
time point 





Figure 36. Hierarchical cluster analysis of total proteomic profile revealed that treated and 
control samples did not cluster separately and that there was no clustering by harvest timepoint 
a T1: 6 hours post treatment. b T2: 24 hours post treatment. c T3: 48 hours post treatment d all time 























































































































































Differential expression analysis 
 
Protein groups differentially expressed between BME and HIV- Tat treated samples 
(p < 0.05), per time point, were visualized by volcano plot (Figure 37). Significantly 
differentially expressed protein groups were taken forward for biological significance 
analyses and comparison to differentially expressed protein groups from time course 
data of cells differentiated at 90% cell confluence. 
Figure 37. Visual representation of expression changes between HIV-Tat treated and control 
samples for lower cell confluence time course experiment protein groups plotted as a function of 
significance (-log10 p value) and log2 fold change (log2FC). a T1: 6 hours post treatment b T2: 24 hours 
post treatment c T3: 48 hours post treatment. FC: Fold change = TAT/BME. Horizontal line indicates p 
= 0.05 (level of significance set for the independent t test analysis per protein group). Vertical lines 
indicate two fold change in expression (±log21). Up-regulated protein groups coloured green, down-
regulated protein groups coloured red. BME - control. TAT - HIV-Tat treated. 
 
5.6.3 Comparison of sample preparation across time course experiments 
Cell counts were largely uniform across samples (low standard deviation for cell 
counts, Table 17) suggesting robust cell culture plating. BCA quantitation provided 
additional support that samples differentiated at 70% cell confluence indeed contain 
lower levels of total protein - seemingly as the result of fewer cells - than cells 
differentiated at 90% cell confluence (Table 17, Table 16, Table 2). In addition, 
protein amount per cell correlated between the two experiments (Table 17) 
suggesting uniformity in protein production at the cellular level despite differences in 
cell confluence. One could hypothesise that fewer cells imply a lower number of 
 a T1 (6 hours) b T2 (24 hours) c T3 (48 hours)  
73 
neuronal processes and lower synaptic density, which was visually evident from the 
cell culture dishes (data not shown).  
Table 16 Cell counts and protein quantitation for time course experiment (cells differentiated 
at 70% cell confluence) 






per cell (pg) 
T1_BME1 8.73 x 105 0.57 38.59 44.203 
T1_BME2 4.2 x 105 0.60 37.98 90.42 
T1_BME3 1.74 x 106 0.69 39.81 22.80 
T1_BME4 1.65 x 106 1.11 67.82 41.10 
T1_TAT1 1.68 x 106 1.03 74.01 44.05 
T1_TAT2 4.13 x 105 0.21 13.99 33.87 
T1_TAT3 8.73 x 105 0.73 47.012 33.58 
T2_BME2 8.3 x 105 0.98 58.50 70.48 
T2_BME3 2.38 x 106 0.78 49.91 24.35 
T2_BME4 8.3 x 105 0.87 56.028 34.16 
T2_TAT1 2.05 x 106 0.89 62.92 37.31 
T2_TAT3 1.64 x 106 0.91 63.70 26.76 
T3_BME1 1.046 x 106 0.77 55.23 52.80 
T3_BME3 1.51 x 106 0.57 42.408 28.75 
T3_BME4 1.095 x 106 0.61 38.962 35.58 
T3_TAT1 1.48 x 106 0.87 55.071 37.21 
T3_TAT2 1.88 x 106 0.74 51.8 27.55 
T3_TAT3 1.73 x 106 0.76 53.68 31.028 
* T1_: time point 1; T2_: time point 2; T3_: time point 3; TAT: HIV-Tat treated; BME: control.
**Cell counts from 6cm cell culture dishes
Table 17 Comparison of cell culture parameters for cells 
differentiated at 70% versus 90% cell confluence 




Average cell count 1.32 x 106 
± 0.60 x 106 
2.77 x106 
± 0.55 x 106 
Average protein 








5.6.4 Biological significance analysis 
For the lower cell confluence experiment, trends for normalised and un-normalised 
protein groups per Panther protein class mirrored those seen in the higher cell 
confluence experiment (Figure 38, Figure 19). Indeed, the trends of un-normalised 
protein groups, and protein groups normalised to the full list of protein groups 
identified per time point, were almost identical (Figure 38a and b). In addition, the 
trend change between un-normalised protein groups (Figure 38a) and protein groups 
normalised to the number of differentially expressed protein groups per time point 
(Figure 38c) may be explained by the trend in the number of differentially expressed 
protein groups over time (Figure 39). The protein classes cytoskeletal protein and 
nucleic acid binding - which were affected by HIV-Tat treatment in cells 
differentiated at 90% cell confluence - were also analysed in HIV-Tat treated cells 
differentiated at 70% cell confluence, as discussed below. 
When cytoskeletal protein was considered, it was apparent that trends were 
comparable across the two independent time course experiments (Figure 40c), 
including the observation that most, if not all, of the protein groups were down-
regulated in response to HIV-Tat treatment across all time points (Table D1-3, 
Appendix D; Tables B4-6, Appendix B). However, the proportion of protein groups 
that mapped to this protein class was much lower for the lower cell confluence 
experiment (Figure 40c). Further, there was little evidence of over/under-
representation (in relation to the ‘background list’) of protein classes that belonged to 
the same parent lineage as cytoskeletal protein at all three time points for cells 
differentiated at lower confluence (Tables 18-20). 
When nucleic acid binding was considered, the trend - in terms of the 
proportion of protein groups that mapped to this protein class per time point - 
mirrored that of the higher cell confluence experiment (Figure 40c). In addition, 
protein classes in the same parent lineage as nucleic acid binding were significantly 
over/under represented in comparison to background for the lower cell confluence 
experiment (p < 0.05) (Tables 18-20). For example, the class histone (PC00118) was 
over represented greater than 5-fold at 6 hours post treatment (p = 3.16e-2) (Table 
18), the class centromere DNA-binding protein (PC00071) was over represented 
greater than 5-fold at 24 hours post treatment (p = 5.07e-3) (Table 19), and the class 




hours post treatment (p = 2.13e-3) (Table 20) in relation to the background (i.e. full 
list of all identified protein groups). Further, when the functions and up-/down-
regulation (log2 fold change in expression values) of the implicated protein groups 
were considered, the two independent time course experiments were largely in 
agreement (Tables D4-6, Appendix D; Tables B1-3, Appendix B). Trends pertaining 
to nucleic acid binding over time for the lower cell confluence experiment are 
explained in more detail below. 
At 6 hours post treatment, most nucleic acid binding protein groups were down-
regulated (Table D4, Appendix D). While this appeared contrary to the higher cell 
confluence experiment at first glance - where such protein groups were largely up 
regulated (Table B1, Appendix B) - these protein groups (in the lower confluence 
experiment) were involved in chromatin condensation (Table D4, Appendix D) and 
down-regulation of these protein groups would presumably allow for overall 
increased gene expression. Therefore, this is in fact consistent with functional changes 
at 6 hours post treatment in the higher cell confluence experiment. Surprisingly, 
however, pre-mRNA processing appeared to be down-regulated at this time point in 
the lower cell confluence experiment (Table D4, Appendix D), while mRNA 
processing was up-regulated at this time point in the higher cell confluence 
experiment (Table B1, Appendix B).  
At 24 hours post treatment - when the least number of protein groups mapped to 
nucleic acid binding - there appeared to be an up-regulation of gene expression 
inhibition genes (e.g. CBX8, SRS10, PRKRA) (Table D5, Appendix D) suggesting 
down-regulation of gene expression at this time point. This was in agreement with the 
24-hour time point in the higher cell confluence experiment.  
At 48 hours post treatment, most protein groups were down-regulated, but had 











Figure 38. Functional classifications of differentially expressed protein groups over time, 
according to Panther protein class, for the lower cell confluence experiment a absolute number of 
genes per time point. b number of genes normalised to the full list of identified genes per time point. c 
number of genes normalised to the number of differentially expressed genes per time point. Gene name 





Figure 39. Venn diagram showing overlap of proteins groups between different time points  
a Overlap from differentially expressed protein groups list. Circles are drawn to scale. Time points T1, 
T2 and T3 (6, 24 and 48 hours, respectively).  b Overlap of ‘full list’ – i.e. all protein groups identified 
in all experimental and all control samples for that time point. Time points T1, T2 and T3 (6, 24 and 48 
hours, respectively). c Number of protein groups (represented by gene IDs) identified at each time 
point. Differentially expressed genes meet a cut-off of p < 0.05. T1: 6 hours post treatment, T2: 24 
hours post treatment, T3: 48 hours post treatment. Venn diagrams generated using Venny online tool: 
www.stefanjol.nl/venny. 






T1 1682 34 
T2 2294 88 








Figure 40. Trends of differentially expressed protein groups that mapped to the protein classes 
nucleic acid binding and cytoskeletal protein across time and cell confluence a Absolute number of 
genes per time point. b Number of genes normalised to the full list of identified genes per time point. c 
Number of genes normalised to the number of differentially expressed genes per time point. H: higher 
cell confluence time course experiment (cells differentiated at 90% cell confluence). L: lower cell 
confluence time course experiment (cells differentiated at 70% cell confluence). T1: 6 hours post 






Table 18 Top 11** output from over/ under representation analysis of Panther protein class terms at 











































































102 5 2.19 + 2.29 6.38E-
02 
** please note that not all Panther protein classes listed are significantly over/ under represented 
(check p.value column) 
* The number of protein groups belonging to background (i.e. full list) and differentially expressed protein
group may not correlate with the values in Figure 39c as the Panther algorithm could not map all protein




Table 19 Top 10** output from over/ under representation analysis of Panther protein class terms at 













































































44 4 1.54 + 2.60 6.84E-
02 
** please note that not all Panther protein classes listed are significantly over/ under represented 
 (check p.value column) 
* The number of protein groups belonging to background (i.e. full list) and differentially expressed protein 
group may not correlate with the values in Figure 39c as the Panther algorithm could not map all protein 











Table 20 Top 10** output from over/ under representation analysis of Panther protein class terms at 











































































42 5 2.11 + 2.37 6.09E-
02 
** please note that not all Panther protein classes listed are significantly over/ under represented 
 (check p.value column) 
* The number of protein groups belonging to background (i.e. full list) and differentially expressed protein 
group may not correlate with the values in Figure 39c as the Panther algorithm could not map all protein 













This study aimed to use MS-based discovery proteomic analysis to identify the cell-
wide effects of HIV-Tat on non-transformed, differentiated NES cells over time, 
representing an in vitro model of initial HAND progression. Findings from this work, 
in which clade B HIV-Tat was used, are applicable to the majority of HAND patients 
from Sub-Saharan Africa who are infected with clade C virus with HIV-Tat CC motif 
(dicysteine at position 30-31), as measures of neurovirulence are comparable for clade 
B and clade C HIV-Tat with the CC motif (Rao et al. 2013). 
 We have shown that differentiated NES cells display morphological and 
functional neuronal characteristics. We identified protein groups differentially 
expressed between HIV-Tat treated and control NES cells over time (6, 24 and 48 
hours), at two cell confluences, using MS. In addition, we have largely supported 
findings for the higher (~90%) cell confluence 24-hour time point with a repeat. The 
cells differentiated at higher cell confluence and then treated show that HIV-Tat 
affects nucleic acid binding and cytoskeletal maintenance proteins up to 48 hours post 
treatment. Results from cells differentiated at lower (~70%) cell confluence and then 
treated mimic these trends for both nucleic acid binding and cytoskeletal protein 
Panther protein classes. However, the effect to cytoskeletal protein dysregulation is 
not statistically over represented (in comparison to the background proteome) at this 
cell confluence. Relevant sections from the Results are discussed in detail below. 
 
6.1 NES cell line  
The NES cell line represents a novel cell culture system for the study of HAND 
In this study, we established the differentiated NES cells as a cell culture model 
representing HAND and showed that these cells display neuronal morphology at 9 
days post differentiated (Figure 6b).  
Further, we provided evidence for the presence of functional neuronal 
characteristics in these cells using the electrophysiological, patch-clamp technique. 
This technique, which allows for the measurement of passive electrophysiological 
properties of a cell by controlling the voltage or current passing through the cell, is 




While the electrophysiology study performed here was only a pilot (as more 
cells are typically recorded in order to increase confidence in findings), it is clear that 
differentiated NES cells displayed properties of neuronal tissue (Figure 7). This was 
apparent from the visual appearance of differentiated NES cells (Figure 7a and 
Figure 6b), the ability of NES cells to generate action potentials (Figure 7b-d) and 
the observation of additional membrane parameters characteristic of neurons (Figure 
7e-f). It must be noted that the IR was a bit higher than expected (Telias et al. 2014), 
which is relevant because IR is inversely proportional to neurite outgrowth and the 
increased number of ion channels inserted into the plasma membrane - a process that 
occurs during the process of neuronal maturation (Moody & Bosma, 2005) - and 
therefore, one would expect a low IR measurement for mature neurons. Further, 
average maximum INa+ and IK+ were slightly lower than expected (Telias et al. 2014; 
Song et al. 2013). These observations could therefore indicate that the NES cells were 
not fully mature in their electrophysiological activity at the time of the experiment. In 
support, Tailor et al. (2013) show that the NES cells continue to mature up to four 
months after differentiation. 
One may argue that a mono-population of fully mature neurons in culture 
wouldn’t have the in vivo pressures (from other cell types etc.) to change. Indeed, cell 
culture models studying plasticity invariably work with mixed cell populations of 
neurons and glia (Zemianek et al. 2012). This could be the case with the NES cells, 
which differentiate into only GABAergic and glutamatergic neurons (i.e. no glia) 
(Tailor et al. 2013). Therefore by choosing an earlier time point when the proteome of 
the NES cells are relatively stable (Garnett, unpublished) and when the cells produce 
action potentials (Figure 7) (but the cells are not necessarily fully mature) one may be 
able to ‘construct’ plasticity. As neuronal plasticity is crucial in forming synapses, 
and as the synapse is, in turn, the crucial molecular component for learning and 
memory (Mayford et al. 2012), plasticity is especially important in the study of 
HAND given the learning and memory deficits that characterise this illness. The NES 
cell line used in the current research therefore represents a physiologically relevant 
and novel system for the study of HAND. 
The observation of neuronal characteristics in the differentiated NES cells 
corroborated expected morphological differences between NES cells in the stem cell 
and differentiated state (Figure 6) (Tailor et al. 2013). Findings were further 




expression of NES cells between 8 and 12 days post differentiation (Garnett, 
unpublished), indicating that the cells were no longer in a proliferative state at the 
chosen time point (post differentiation) for treatment. While electrophysiological 
properties have been studied previously in differentiated NES cells as mentioned 
(Tailor et al. 2013), characterisation had not previously been carried out for NES cells 
as early as 9 days post differentiation. 
6.2 Assessment of protein preparation procedures 
Cell count and protein quantitation correlated well (Table 2), indicating that BCA 
quantitation was sufficient to estimate total cell protein. While HT2_BME samples 
seemed to have slightly more protein yield per cell than the other samples (Table 2) 
this did not affect MS analysis as was evident from no observed systematic technical 
error across samples (Figure 15 and 16). A total of 30μg protein was taken from each 
cell pellet for MS analysis, which was ample protein considering that not more than a 
hundred ng of protein is required for a MS experiment and that some protein loss may 
occur during processing (Mann, FASP protocol: lower and upper limits for FASP 
MWCO filters is 10μg and 200μg, respectively; Wiśniewski et al. 2009). In a label 
free MS experiment, it is important to ensure that equal quantities of peptide are 
loaded per sample, as all parameters - other than the parameters explicitly being tested 
(i.e. experimental conditions) - must be kept constant in order to make meaningful 
comparisons between MS runs. Further, the amount of peptide loaded must be kept 
constant across samples in order to compare protein quantity across runs and to make 
inferences about the individual protein groups that make up the total protein pool. In a 
label-free MS experiment, each sample is run on the MS instrument separately and, 
unlike during a labeled method (e.g. SILAC or iTRAQ), there are no internal 
standards for base value normalisation (Bantscheff et al. 2007). As such, consistency 
of experimental parameters is of the utmost importance. 
 FASP was chosen as a proteome processing protocol, as it efficiently removes 
residual SDS originating from the lysis buffer. It is important to remove SDS, as it 
would affect tryptic digestion and it ionises more readily than peptides to significantly 
increase background spectra (Wiśniewski et al. 2009). Peptides were desalted after 
FASP, as salts - i.e. other ionic compounds - also interfere with ionisation of peptides 
during ESI (Wiśniewski et al. 2009).  
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6.3 MS-based proteomic analysis: time course experiment of NES cells 
differentiated at 90% cell confluence 
6.3.1 Assessment of MS data quality and raw data processing 
A total of 1 067 211 spectra were recorded, of which 53.28% were mapped to known 
protein groups by MaxQuant software, corresponding to a total of 4104 protein 
groups across the 20 samples analysed. In order to increase confidence in findings, a 
protein group was only taken forward for comparison across experimental conditions 
if that protein group was observed in all replicates of a given condition (a parameter 
aided by MaxQuant’s LFQ ‘match between runs’ function during raw spectra 
processing). Therefore, the more protein groups identified across all samples, the 
more complete our insights into the effect of HIV-Tat treatment on the neuronal 
proteome was. However, a snapshot of even just the most abundant (and thus perhaps 
functionally dominant) proteins in a cell at any given time should give one a good 
idea of the physiological affects of treatment. Considering a recent estimate that 3000 
proteins constitute ~99% of the protein mass of a mammalian cell (Wiśniewski et al. 
2012), it is encouraging that this work identified 2314 protein groups (~77% of the 
3000 most abundant proteins) common to all HIV-Tat-treated  and control samples.  
Identity assignment to 53.28% of the mass spectra is in line with what is 
expected from the Andromeda search algorithm used in this work (Cox et al. 2011), 
and is among the highest achieved in the Blackburn laboratory, which typically ranges 
from 30-50% depending on the sample type and origin (unpublished). Spectra not 
assigned may have low spectral signal-to-noise ratios, which may be introduced if two 
different peptide precursor ions, that have co-eluted and enter the mass analyser at the 
same time, are simultaneously selected for MS2 fragmentation. Alternatively, the 
actual background noise may be high compared to the signal as the result of poor 
proteome processing - incomplete desalting, for example. 
High data quality is also supported by the finding of good tryptic digestion of 
samples, with an average of 80.6% no missed cleavages (Figure 13). It is important 
that tryptic digestion of the proteome be as complete as possible in order to produce 
peptides in the optimal mass range for MS sequence identification (Duncan et al. 
2010) thereby allowing for appropriate proteome (and individual protein) coverage. In 
addition, the dataset had a low absolute mass error of 0.7 ± 1 ppm (Figure 14) (the 




average measured peptide mass when compared to theoretical peptide mass generated 
by in silico digestion of the provided protein database (Cox et al. 2009). Consistent 
and low mass error across samples indicates MS instrument accuracy and stability.  
Moreover to data quality, TIC profiles were all of the desired intensity 
(maximum of ± 5.5e9), indicating correct concentration of the peptide sample for 
optimal identification of peptide ions (examples of appropriate TICs at the MS and 
MS2 levels can be viewed in Figure 12e). Further, data was collected along the entire 
length of the chromatogram in defined peaks indicating good separation of the peptide 
sample during online HPLC (e.g. Figures 12e). Good separation of peaks - and thus 
increased resolution - is important for accurate assignment of mass spectra, and 
affects the mass error calculation. 
 
6.3.2 Statistical analyses 
LFQ expression values per protein group were used to determine statistical 
differences between samples. To aid visualisation of the data (boxplots, scatterplots, 
hierarchical clustering and volcano plots), LFQ values were log2 normalised. For 
differential expression analysis, LFQ values were not normalised. While HIV-Tat 
treated and control samples appeared to cluster separately for all 3 time points 
(Figure 17a-c), the samples were actually quite similar, as indicated by long 
dendrogram branches calculated by the Euclidian model of absolute distance. This 
was supported by scatterplot representation, which showed linear relationships (i.e. 
similarity) across experimental conditions (Figure 15a-c, R2  > 0.95). The observed 
clustering by time point across experimental conditions (Figure 17d) may be the 
result of subtle experimental errors during cell harvesting at the different time points. 
However, this clustering was also weakly correlated, as indicated by imperfect 
separate clustering of time points (Figure 17a-c) and by similarity of LFQ value 
range across samples as seen by boxplot analysis (Figure 16), which revealed no 
systematic technical error across samples. Further, as mentioned, each treated group 
was only compared to the control group from that time point, so any experimental 
effects common to a time point should not bias downstream analyses. 
Despite overall similarities in protein expression, more subtle differences on a 
per-protein-group per time point level were revealed by hypothesis testing (Figure 




control samples per time point were subtle (Figure 18, -1 < log2FC < 1), but 
statistically significant (p < 0.05). A total of 131, 118, and 45 protein groups were 
identified as being significantly differently expressed at 6, 24, and 48 hours post HIV-
Tat treatment, respectively (Table 3). These lists of differentially expressed protein 
groups per time point were taken forward for biological significance analysis. 
 
6.3.3 Biological significance analysis 
Functional classification into Panther protein classes elucidated the biological 
significance of protein groups differentially expressed in response to HIV-Tat 
treatment over time. This represents a protein-centric approach to biological 
significance analysis, versus a protein families approach, in which Gene Ontology 
classifications are typically used (Harris et al. 2004). A protein-centric approach was 
a relevant type of analysis for the current work given the strong statistical evidence on 
a per peptide basis, as indicated by low PEP scores (Tables B1-B6, Appendix B). A 
decision was made to focus on differentially expressed protein groups in the context 
of functional classifications (versus a focus on the function of individual protein 
groups in isolation or a focus on the most up-/down- regulated protein groups) as very 
interesting overarching trends - pertaining to fold change direction (up- or - 
regulation) of individual protein groups and to broader functions - were observed 
when the data was analysed in this way. This ‘strength in numbers’ approach revealed 
biologically significant phenomena, as detailed below.  
The observation that trends over time were almost identical for un-normalised 
class-mapped protein groups and class-mapped protein groups normalised to the full 
list of protein groups identified (Figure 19a and b) indicates that these trends were 
not merely a function of the number of protein groups identified by the MS 
instrument per time point (i.e. technical variability). As mentioned in the results 
section, trends were largely maintained when class-mapped protein groups were 
normalised to the number of differentially expressed protein groups for a particular 
time point, except at time point 3 for some protein class trends. For these few, there 
was a downward trend between time points 2 and 3 before normalisation, and a ‘u’-
shaped trend after normalisation (Figure 19c). This was most probably due to a 
decrease in the number of differentially expressed protein groups observed over time 




protein groups that mapped to some protein classes (in absolute numbers) over time 
(Figure 19b, most notably nucleic acid binding), the trend - with respect to the 
proportion of protein groups per protein class compared to the number of 
differentially expressed protein groups per time point (Figure 19c) - represents a 
specific process, in which the proportion is meaningful. This is in opposition to a 
situation in which there is a decrease in the absolute number of protein groups over 
time, but the proportion remains constant, which would suggest a non-specific 
process.  
Trends of the abovementioned ‘proportion’ may then be combined with data 
concerning up or down-regulated expression (log2 fold change) of protein groups 
belonging to the protein classes of interest, in order to further elucidate the biological 
effects of HIV-Tat treatment on neurons over time, as discussed. In terms of further 
analyses, the protein classes nucleic acid binding and cytoskeletal protein were 
looked at in closer detail (Figures 19 and 20). While these protein classes themselves 
were not necessarily significantly over/under represented (compared to background), 
many protein classes functionally linked to these classes - via Panther class parent 
lineage - were over/under represented and occurred in the top 10 Panther protein class 
mappings for over/under representation analysis (p ≤ 0.06 - data dependant arbitrary 
cut-off for significance, individual p values quoted at relevant points in the text 
below; Tables 7-9). Further, as this was a protein-centric approach, log2 fold changes 
in expression on a per protein group basis, or per group of protein groups, were 
important to take into account: if a collection of protein groups, which all map to the 
same protein class, showed the same effect in terms of up or down-regulation in 
response to treatment at a particular time point, then this phenomenon was of interest. 
It points to the effect of HIV-Tat treatment on the ‘direction’ (up or down) of 
regulation of a cellular function. As such, trends pertaining to the protein classes 
nucleic acid binding and cytoskeletal protein were analysed in greater detail (see 
below). 
 
HIV-Tat affects differentiated neurons at the level of gene expression machinery 
 
One may argue that, theoretically, the nucleic acid binding class would always end up 




protein classes (Figure 19)], as there are more RNA and DNA binding proteins than 
all other proteins in the mammalian cell, including brain cells (Gerstberger et al. 
2014). Conceptually similarly, one may also argue that there should always be more 
RNA binding than DNA binding protein groups in a dataset (Figure 20a), since there 
are more RNA binding proteins than transcription factors in mammalian cells 
(Gerstberger et al. 2014). Indeed, as mentioned, the protein class nucleic acid binding 
itself was not significantly over/under represented when compared to background 
(Tables 7-9). However, significantly over/under represented protein classes that were 
functionally linked - and that shared the same parent lineage to this broad class - were 
apparent. For example: the class RNA methyltransferase (PO00033) was over-
represented 5-fold at 6 hours post treatment (p = 5.52e-3; Table 7); the class DNA 
binding protein (PO00009) was under-represented less than 0.2-fold at 24 hours post 
treatment (p = 2.47e-2; Table 8); and the class DNA binding protein (PO00009) was 
over-represented 2.34-fold at 48 hours post treatment (p = 6.08e-2; Table B9).  
In addition, over/under representation data correlate well with expression 
change trends (log2 fold change). That is to say, an over representation of a protein 
class functionally linked to nucleic acid binding was associated with up-regulation of 
the specific protein groups that map to nucleic acid binding (Tables B1-3, Appendix 
B; Tables 7-9). The combined weight of these evidences makes it unlikely that the 
size of this category biased the trend in nucleic acid binding protein groups observed 
over time. Perhaps the absolute number of protein groups that mapped to this protein 
class was not as vastly different to the other classes as was suggested by the figures 
(Figure 19), but the trend, particularly in terms of the change in ‘direction’ of 
expression over time, appeared to be significant. 
In further elucidation of the nature of this trend, it was apparent that a higher 
proportion of protein groups were mapped to nucleic acid binding at 6 and 48 hours 
post HIV-Tat treatment, compared to 24 hours post HIV-Tat treatment (Figure 19c). 
This was maintained at both the DNA and RNA levels (Figure 20a), indicating an 
effect on both transcription and translation machinery. Further, this trend was in 
agreement with another overall trend in which expression of the differentially 
expressed protein groups that mapped to nucleic acid binding were up-regulated at 6 
hours post treatment, followed by down-regulation at 24 hours, and finally up-
regulation at 48 hours (Tables B1-3, Appendix B). The observation that many protein 




particular time point, increases confidence in the observed effects of HIV-Tat 
treatment.  
 
The observed ‘u-shaped’ trend in ‘nucleic acid binding’ over time could be explained 
in terms of a ‘competition’ between HIV-Tat and the host 
 
The above hypothesis can be explained as follows: 
Initially (as measured at 6 hours post treatment), HIV-Tat directly up-regulates 
expression of protein groups with nucleic acid binding activity either directly, through 
HIV-Tat’s transcription factor activity, or indirectly, by HIV-Tat’s activation of other 
proteins, such as host transcription factors. This is plausible given HIV-Tat’s role as a 
transactivator of transcription for the HIV genome, and its ability to bind many 
human genome loci and to recruit and bind many host factors (Gatignol 2007; Marban 
et al. 2011; Gautier et al. 2009; Debaisieux et al. 2012). Moreover, this suggests that 
HIV-Tat’s inherent ability to alter gene expression may extend further than just the 
HIV genome (i.e. to the human genome), as has previously suggested by the effect of 
HIV-Tat on expression of specific host factors (Flores et al. 1993; Buonaguro et al. 
1994). It would be interesting to use a ChIP-seq approach in the current cell line to 
determine genome-wide binding sites of HIV-Tat in non-transformed neurons, which 
may aid in determining the biological processes that HIV-Tat dysregulates - to 
contribute to HAND pathogenesis - by analysing genes encoded downstream of these 
binding sites. Nucleic acid binding protein groups are presumably targeted by HIV-
Tat, as these proteins comprise the transcriptional and translational machinery of the 
cell, much of which is recruited by HIV-Tat for HIV genome replication.  
This initial up-regulation of ‘gene expression machinery’ protein groups was 
followed by an overall down-regulation of ‘gene expression machinery’ protein 
groups - as well as fewer of these proteins differentially expressed - at 24 hours post 
treatment. This, to extend the hypothesis, perhaps indicates a host response attempting 
to curb HIV-Tat’s effects and regain host cell homeostasis. Then, as HIV-Tat 
degrades in the cell as per its half-life and/or as it is actively cleared (both of which 
are not well documented in the literature), gene expression machinery proteins may 
increase again to compensate for previous decreased functioning. This can be seen at 
48 hours post treatment where there was an increase in the proportion of protein 
groups mapped to this protein class (Figure 19c), as well as an up-regulation in 
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expression (log2 fold change) of the corresponding individual protein groups (Table 
B3, Appendix B). One could further hypothesise that gene expression machinery 
proteins will no longer be differentially expressed and will reach baseline/control 
levels at time points beyond 48 hours, assuming no additional active HIV-Tat is 
added to the system.  
Alternatively, the up-regulation of gene expression machinery at 48 hours post 
treatment may be a second, slower response that is perhaps only apparent after 48 
hours. This points to the importance of extending the time course shown in the current 
work in order to understand longer-term effects of HIV-Tat and cell recovery post-
exposure (see section 8. Future work). If this second, related or unrelated, response 
does continue long-term, one might draw parallels between the trends in nucleic acid 
binding in HIV-Tat treated neurons and other biphasic biological responses in nature, 
such as the Mycobacterium tuberculosis (Mtb) hypoxic response (Figure 41). Under 
oxidative stress, Mtb initially up-regulates Dos regulon (stress response) genes 
followed by a cessation of this response after 24 hours (Rustad et al. 2008). This is 
followed by another, longer and enduring response, termed the enduring hypoxic 
response (Rustad et al. 2008). There is little overlap in the genes involved in the two 
waves of the response, similarly to what is seen in the current work (Figures 21). It is 
therefore plausible that a similar biphasic response mechanism is occurring within the 
gene expression machinery of HIV-Tat treated neurons (Figure 41). 
Figure 41. Changes to nucleic acid binding protein groups over time, in HIV-Tat treated neurons, 
may follow a biphasic trend The time points on the diagram (6, 24, and 48 hours) represent time 












Dysregulation of cytoskeletal maintenance proteins by HIV-Tat may be the molecular 
mechanism of synaptodendritic injury seen in HAND patients 
 
The observation that proportionally and progressively more actin related proteins 
were differentially expressed over time (Figure 20b) was in agreement with 
continued repression of these protein groups (i.e. negative log2 fold change expression 
values at all 3 time points; Tables B4-6, Appendix B) and suggest that the effect on 
cytoskeletal instability was sustained, perhaps strengthened over time. This 
observation was supported by over/under representation analysis, in which, for 
example, the protein class extracellular matrix protein (PO00102) - involved in 
synaptic plasticity (Frischknecht & Gundelfinger 2012) and physically linked to the 
actin cytoskeleton via cell adhesion molecules (Geiger et al. 2001) - was significantly 
over represented at 48 hours post treatment (p = 2.26e-2) (Table 9). It is worth 
clarifying that one may observe down-regulation (in terms of log2 fold change) of a 
particular set of protein groups, but over representation of the protein class - to which 
the set of protein groups belong - in comparison to the background proteome (i.e. 
Fischer’s exact test). This indicates that the implicated protein class (or broader 
function) was targeted by the treatment - specifically, that the treatment down-
regulated many of the individual members of this protein class. 
As the cytoskeleton is crucial for synaptic maintenance (Lin & Koleske 2010), 
and therefore neuronal communication (Goellner & Aberle 2012), dysregulation of 
cytoskeletal maintenance proteins - as seen in the current work after HIV-Tat 
treatment - would affect synapses and neuronal processes. The effect of HIV-Tat on 
the cytoskeleton may therefore explain/contribute to the clinical phenotype of 
structural brain alterations observed in HAND patients (Ragin et al. 2012). As 
examples of in vitro support for this line of reasoning: Kim et al. (2008), found that 
rat hippocampal neurons treated with HIV-Tat in vitro underwent synaptic 
degradation; and HIV-Tat treatment has been shown to cause cytoskeletal 
dysregulation in T lymphocytes (Lopez-Huertas et al. 2010).  In addition, 
experimental evidence showing that HIV-Tat treatment caused grey matter deficits 
and impaired learning and memory in mice (Carey et al. 2012; Carey et al. 2013) 
further supports the argument that HIV-Tat detrimentally affects the synapses, which 
are widely known to be crucial in learning and memory (Mayford et al. 2012). Indeed, 




paraplegias, have been linked to cytoskeletal damage (Goellner & Aberle 2012).  It is 
therefore plausible that something similar is happening during the molecular 
pathogenesis of HAND.  
Interestingly, cytoskeletal alterations have been associated with HIV-infected-
monocyte interactions with the BBB (Woollard et al. 2014) possibly aiding entry of 
infected monocytes into the central nervous system. It is less clear whether 
cytoskeletal dysregulation affords any advantages - in terms of viral propagation - in 
the context of HIV-Tat infected neurons, or whether it is a ‘carry over’ from an 
evolved effect in infected monocytes (or other HIV infected cells).  
Here, we suggest, for the first time (to our knowledge) that synaptic degradation 
in HAND may be due to down-regulation of cytoskeletal maintenance proteins, and 
thus cytoskeleton instability (Figure 42). It is important to note that damage to the 
synapses has been shown to be reversible (Ellis et al. 2007; Ragin et al. 2012); 
therefore it may be beneficial to focus on prophylactic drug development or early 








Figure 42. Down-regulation of cytoskeletal maintenance proteins by HIV-Tat may be the 
molecular correlates of synaptic degradation in HAND patients Schematic diagram of hypothesised 
HIV-Tat effects on the neuronal cytoskeleton after up to 48 hours of HIV-Tat treatment. 
 
There is no evidence of dysregulated calcium metabolism at 6 hours post HIV-Tat 
treatment 
 
As mentioned, the 6-hour time point was selected in an effort to identify proteomic 
signatures that may support literature relating to calcium influx (and therefore 
neuronal excitotoxicity) as a result of HIV-Tat treatment (Krogh et al. 2014). 
Although it has previously been shown that there is a large calcium influx in response 
HIV-Tat 
neuron 





healthy synapse damaged synapse 
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to HIV-Tat treatment up to 8 hours after treatment, followed by a cessation of this 
effect (Krogh et al. 2014), no such evidence was found in the current work. This may 
be due the time point chosen; perhaps 6 hours post HIV-Tat treatment is not optimal 
to observe this effect. Alternatively, it may be due to the fact that calcium influx 
occurs as the result of cellular processes not ‘visible’ to the current approach, which 
only measured protein expression changes (see 7. Limitations). Such a cellular 
process could, for example, relate to altered protein activity due to post-translational 
modifications, which this experiment was not designed to consider. It is also plausible 
that differences exist between the neuronal cell model used in the above-mentioned 
study and in the current work. 
Protein groups differentially expressed at more than one time point may highlight key 
points/pathways along the progression of HIV-Tat’s effects 
Little overlap in protein groups identified at progressively later time points post 
treatment may demonstrate the progression in cell response to HIV-Tat treatment over 
time (Figure 21b). Further, the protein groups that were differentially expressed at 
more than one time point may highlight particular biological functions that were 
affected by HIV-Tat treatment (Tables 10-12). As mentioned, all peptides used to 
identify a particular protein group in the current work had low PEP scores (< 0.01), 
indicating confidence in the assignment of a particular mass spectrum to a particular 
tryptic peptide identity (Tables B1-6, Appendix B), and thus confidence in making 
hypotheses about particular protein groups, or clusters of protein groups, identified in 
the current experiments.  
As an example of protein groups expressed at more than one time point, many 
nucleic acid binding class protein groups were up-regulated at 6 hours post treatment, 
and subsequently down-regulated at 24 hours post treatment (Table 10). This was 
consistent with functional classification into Panther protein classes, which indicated 
that protein groups that mapped to nucleic acid binding were largely up-regulated at 6 
hours post treatment, and subsequently down-regulated at 24 hours post treatment 
(Tables B1-2, Appendix B). The observation that many individual protein groups 
followed this trend in expression over time further strengthens the hypothesis that 
HIV-Tat treatment causes an initial up-regulation and subsequent down-regulation of 




there is something important about the functions of these particular protein groups. As 
an example, MRPL45 encodes the 39s mitochondrial ribosome subunit (GeneCards) 
(Table 10). Down-regulation of this gene at 24 hours post treatment would have a 
significant effect on translation of mitochondrial genes and perhaps cell energy 
metabolism.  
In addition, some protein groups were differentially expressed at both 6 and 48 
hours post treatment (CO3A1, CTNA1, SNX27). As these protein groups were all 
present in the ‘total list’ for the 24-hour time point (raw data not shown), this 
phenomenon cannot be explained by these protein groups going undetected by the MS 
instrument at 24 hours post treatment (Figure 21a). Rather they were not significantly 
differentially expressed between treated and control conditions at 24 hours post 
treatment. It is therefore noteworthy that these proteins were significantly 
differentially expressed at 6 hours and then again at 48 hours post HIV-Tat treatment, 
implying that this was not a prolonged effect over 48 hours, but that the same gene 
expression changes occurred again at a second time point. This recurrence of the 
effect was supported by the observation that the same ‘direction’ (up or down) of 
expression regulation (log2 fold change) occurred at the second time point. The genes 
that encode these protein groups are not located on the same chromosome 
(GeneCards), so the trend cannot be explained by co-expression due to proximity of 
genetic loci. It is interesting to note that all protein groups differentially expressed at 
both 6 and 48 hours post HIV-Tat treatment were cytoskeletal/membrane associated 
proteins (Table 12).  
Without careful experimental research into each one of these protein groups’ 
function in a neuron, it is difficult to elucidate how they might be targeted by HIV-Tat 
treatment specifically, and what the downstream biological effects of this might be. 
Therefore, the protein groups that are differentially expressed at more than one time 
point are interesting candidates for follow-up validation work, as possible targets for 
the diagnosis/treatment of HAND and give further evidence for the molecular 






6.4 24-hour time point repeat 
The 24-hour time point repeat largely supported findings from the time course 
experiment 
Results from the 24-hour time point repeat experiment further strengthened the 
evidence for down-regulation of cytoskeletal maintenance processes as the result of 
HIV-Tat treatment (Figure 29, Table 14). Surprisingly, though, while many protein 
groups mapped to the nucleic acid binding class in this repeat dataset, the fold change 
expression differences were not in agreement across the two datasets. In fact, the 24-
hour time point repeat data correlated better with the 6-hour than the 24-hour time 
point (HT2) from the time course experiment.  
An explanation for this discrepancy may be as follows: the 24 hour time point 
repeat was a standalone experiment, whilst HT2 was harvested and processed in the 
context of additional synchronised time points and therefore, it is conceivable that 
these two ‘identical’ time points are in fact out of phase. As the time course 
experiment was synchronised, it is more likely that experimental conditions were 
similar across all time points and therefore it appears more meaningful to analyse 
differences between time points within the time course experiment than to compare 
across different isolated experiments. 
The observation that cytoskeletal maintenance proteins are down-regulated at 
all three time points of the time course experiment could explain why down-
regulation of this cellular process was also observed for the repeat experiment, even 
though the repeat did not correspond exactly to one of the time points. In fact, this 
supports the hypothesis that HIV-Tat treatment is associated with sustained 
dysregulation of cytoskeletal maintenance, at least up to 48 hours post treatment. 
These findings highlight the importance of looking at a treatment/disease progression 
profile over time, to obtain a better sense of overall trends. 
6.5 Time course experiment with NES cells differentiated at 70% cell confluence 
NES cells differentiated at 70% cell confluence showed less HIV-Tat mediated 




The time course experiment was repeated with cells differentiated at lower confluence 
(70%), in order to determine the effect of cell density on HIV-Tat treatment effects. 
We hypothesised that cells differentiated at 70% confluence would have fewer 
synaptic connections than cells differentiated at higher confluence (90%). Thus, one 
might expect to observe fewer effects to the cytoskeleton (a major component of 
synaptic formation and maintenance) after HIV-Tat treatment of cells differentiated at 
lower confluence. We further hypothesised that cell confluence should not result in 
alterations to the gene expression machinery effects of HIV-Tat treatment (as seen 
with cells differentiated at 90% confluence), as this is an intracellular process.  
 
Biological significance analysis 
 
As expected, trends were comparable across the two different cell confluences in 
terms of the proportion of protein groups that mapped to the protein class cytoskeletal 
protein across time (Figure 40c). However, also as expected, cells differentiated at 
70% confluence showed no significant over/under representation effects on the 
cytoskeleton upon HIV-Tat treatment in comparison to the background proteome 
(Tables 18-20). Therefore, it appears that an effect to the cytoskeleton did occur, but 
was not strong enough to meet threshold requirements for statistically significant over 
representation (in comparison to the background) at lower synaptic densities. One 
might hypothesise that if cells are too dispersed, fewer synaptic connections would 
form, resulting in less synaptic activity and, as a result, a ‘smaller’ down-regulation of 
the implicated protein groups in response to HIV-Tat (in comparison to cells with 
many synaptic connections and high synaptic activity). This provides support for the 
notion that HIV-Tat affects the synaptic processes of neurons (Ragin et al. 2012; Kim 
et al. 2008) - as suggested from the statistically significant effect of HIV-Tat on the 
cytoskeleton observed with cells differentiated at 90% confluence - and implicates the 
cytoskeleton as a major molecular structure that becomes dysregulated to cause this 
effect.  
Again, as expected, the effect of HIV-Tat on nucleic acid binding cellular 
functioning was comparable across both cell confluences (Figure 40c). Furthermore, 
this effect was significant for cells differentiated and treated at lower confluence 
(Tables 18-20). For example, protein groups involved in chromatin condensation 
were down-regulated at 6 hours post treatment for both cell confluences, which would 
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presumably facilitate chromatin relaxation and allow for increased viral genome 
transcription (Gatignol 2007). As mentioned, it is plausible that changes to nucleic 
acid binding upon HIV-Tat treatment would not be affected by cell confluence, as this 
class of protein groups is largely involved with intracellular processes. This is in 
comparison to cytoskeletal and synaptic maintenance, which may very well be 
affected by the number of synapses present and consequent levels of communication 
between cells, as described above. 
One discrepancy between the different cell confluence experiments was that 
protein groups associated with mRNA processing were down-regulated at 6 hours 
post treatment for the lower cell confluence experiment (Table D4, Appendix D), 
while they were up regulated at 6 hours post treatment for the higher cell confluence 
experiment (Table B1, Appendix B). This effect - for the lower cell confluence 
experiment - was not intuitive, especially given the central role of mRNA processing 
in HIV protein expression (Hryckiewicz et al. 2011). It is unclear why this effect was 
observed. 
One might argue that the HIV-Tat-concentration:cell-count ratio could explain 
differences between time course experiments at different cell confluences. However, 
if one calculates the number of HIV-Tat molecules present per cell, it is apparent that 
HIV-Tat was applied at a concentration in gross excess to the number of cells, even at 
higher cell confluence. For example, if 2ml medium containing 1ng/μl HIV-Tat (HIV-
Tat ± 10kDa) - which corresponds to 200pmol HIV-Tat - was added to 2 million cells, 
then there would be 1 x 1013 molecules of HIV-Tat in the medium, corresponding to 5 
x 106 HIV-Tat molecules per cell. Further, HIV-Tat’s affinity for certain cell surface 
receptors also ensures that only a certain number of HIV-Tat molecules enter the cell 
at any one time (Richard et al. 2005; Herce & Garcia 2007). Therefore, it is unlikely 
that overall cell count will affect the amount of active HIV-Tat able to enter neurons. 
7. Limitations





MS-based proteomics only reveals changes in de novo protein expression 
 
The particular experimental technique used in the current work only reveals changes 
to protein expression and does not take into account other mechanisms that may 
modulate protein expression and/or function. Importantly, for example, protein 
activation and function should be understood in terms of post-translational 
modification (PTM) status. As phosphorylation is the most ubiquitous PTM (Macek 
et al. 2009), it would be of interest to examine the phosphoproteome of HIV-Tat 
treated differentiated NES cells. In doing so, another layer of biological meaning 
would be added to the current data, perhaps revealing affected pathways that would 
otherwise be overlooked.  
 
The in vivo concentration of HIV-Tat remains unknown  
 
While the concentration of HIV-Tat used here is an accepted estimate, determining 
the true in vivo CNS concentration range of HIV-Tat would allow for a more realistic 
cell culture model of HAND (Xiao et al. 2000; Perry et al. 2010). This limitation may 
be addressed by determining the HIV-Tat concentration in cerebrospinal fluid (CSF) 
from HAND patients, rather than the serum measurement currently used. This may be 
achieved through an enzyme-linked immunosorbent assay (ELISA) or by targeted MS 
analysis of CSF samples (Perry et al. 2010). Discovery proteomics may also generate 
interesting data regarding the proteomic composition of CSF from individuals with 
HAND, and may facilitate identification of candidate diagnostic biomarkers 
corresponding to markers identified in the secretome of cell culture models (e.g. HIV-
Tat treated differentiated NES cells.) As the BBB is compromised during HAND 
progression, it is conceivable that HIV-Tat stimulated markers may be present in the 
CSF (Roberts et al. 2012). 
 
HIV-Tat treatment of a mono-neuronal cell population does not reveal the ‘full 
picture’ of HIV-Tat’s effect in the brain 
 
HIV-Tat is known to affect many brain cell types, and as such, interactions between 
affected cells must be considered to truly make deductions about the effect of HIV-
Tat in the CNS in vivo. Notably, HIV infected glia produce a cytokine storm, which 
produces a significant indirect effect on neurons (González-Scarano & Martín-García 




neuronal and glial populations when growth factors are removed from the medium is 
available in the Blackburn Laboratory (Sun et al. 2008), and may be used in future 
aspects of this project in order to determine the interactions between different HIV-
Tat affected cell types. 
 
8. Future research 
 
Additional experimental time points would allow long-term modelling of the effect 
of HIV-Tat on neurons 
 
The current time course experiment examined the effect of HIV-Tat on neurons at 6 
hours after initial treatment and up to 48 hours post treatment. Findings alluded to a 
particularly interesting biphasic response progression for protein groups that mapped 
to Panther protein class nucleic acid binding (Figure 41). A longer time course would 
reveal the effect of HIV-Tat on neurons at progressively later time points and would 
aid in further elucidating the long-term nature of the response. As differentiated NES 
cell cultures have been maintained for up to four months (Garnett, unpublished), and 
as neurocognitive symptoms may become apparent within the first year of infection 
(Ragin et al. 2012), a realistic model of the temporal progression of HAND can 
potentially now be established. 
 
Validation studies for identified protein groups/pathways of interest 
As with all protein groups identified by discovery proteomics, observations should be 
confirmed by orthogonal approaches, such as Western blot analysis or a targeted MS 
approach. Such studies increase confidence in the differential expression of a 
particular protein as the result of treatment as well as its contribution to a particular 
molecular pathway of interest. Due to the protein groups problem (Nesvizhskii & 
Aebersold 2005), such studies may also identify which particular protein isoform is 
differentially expressed as the result of treatment.  
Of particular interest are those protein groups that are differentially expressed at 
more than one time point, as they allude to the temporal progression of the response 
(Tables 10-12). In addition, gene expression machinery proteins and cytoskeleton 




context of HIV-Tat treated neurons. Perhaps proteins identified through this detailed 
approach - or protein groups differentially expressed at more than one time point - 
could serve as biomarkers for the early progression of HAND (if validated and 
present in easily accessible clinical samples).  
 
Electrophysiological studies of HIV-Tat treated neurons would correlate molecular 
pathology and cell function 
 
Further to the validation of particular protein groups/pathways of interest, additional 
experimental approaches may also increase confidence in findings from proteomic 
experiments. For example, electrophysiological studies of HIV-Tat treated neurons 
over time would allow one to correlate the molecular pathology of HAND (at the 
level of differential protein expression) to cell function changes. In doing so, 
functional consequences of protein expression and PTM changes may be established. 
As these cells are able to generate action potentials and display other neuronal 
characteristics (Figure 7), such an experiment is achievable. 
9. Conclusions 
 
In the current work, longitudinal proteomic analysis of in vitro HIV-Tat treated 
human neurons (differentiated from an NES cell line) showed that the Panther protein 
class nucleic acid binding and cytoskeletal protein were significantly affected by 
HIV-Tat treatment for up to 48 hours post treatment. This suggests that HIV-Tat 
treatment affected the gene expression machinery of the cell, as well as cytoskeletal 
stability, as was suggested from the individual functions of the protein groups that 
mapped to the nucleic acid binding and cytoskeletal protein classes, respectively.  
Changes to the gene expression machinery suggest that HIV-Tat is involved in 
preparing the host cell for increased transcriptional and translational activity. One 
may hypothesise that the observed trend of protein expression (for protein groups that 
mapped to the Panther protein class nucleic acid binding) could be explained in terms 
of a ‘competition’ between HIV-Tat and the host, in which HIV-Tat is derailing the 
status quo and the host is trying to maintain/restore the status quo.  
As the synapse is an intercellular structure degraded in HAND patients and as 
the cytoskeleton is a major component of the neuronal synapse, damage to the 
synapse may be a correlate of cytoskeletal damage upon HIV-Tat treatment. 
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Therefore, cytoskeletal stability may be linked to synaptic integrity. To our 
knowledge, this is a novel association in HAND research and may be of interest in 
determining molecular biomarkers for HAND. The effect to cytoskeletal proteins was 
evident, but less prominent, in cells at low cell confluence, which suggests that 
sparsely plated neurons have fewer synaptic connections and provides support for the 
hypothesis that HIV-Tat is affecting synaptic processes.  
Further, protein groups differentially expressed in response to HIV-Tat 
treatment at more than one time point may represent important molecular switches 
and are good targets for follow up validation work in the identification of molecular 
biomarkers for the characterisation and/or treatment of HAND. The cell culture model 
of HAND established in this work has important implications for HAND research in 
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Table A1. SDS-PAGE gel recipe  
 Stacking gel (5%) Separating gel (15%) 
1M Tris/Cl, pH6.8 (ml) 0.625   - 
1.5M Tris/Cl, pH8.8 (ml)    - 3.75 
30% polyacrylamide (ml) 0.850 7.5 
10% Sodium dodecyl 
sulphate (SDS) (ml) 
0.050 0.15 
10%Ammonium 






dH2O 3.400 3.4 
   
TOTAL volume (ml) 5 15 
 
 
RIPA buffer recipe (adapted from Holden and Horton 2009, buffer 4) 
150mM NaCl 
100mM Tris HCl, pH 7.6 
0.5% Sodium deoxycholate 
1% SDS 







11.2 Appendix B 
Time course experiment (cells differentiated at 90% cell confluence) 
Classifications of differentially expressed protein groups per time point - according to Panther protein class - can be viewed in Tables B1-3 
(nucleic acid binding proteins (PC000171) and B4-6 (cytoskeletal protein PC00085). 
Table B1 HT1 (6 hours post treatment), Differentially expressed protein groups mapped to Panther protein 
class: nucleic acid binding (PC000171) 
geneID gene.name p.value log2FC* subtype PEP 
BAZ1B Tyrosine-protein kinase BAZ1B 0.021 0.16 DNA 9.10e-274 
PARP1 Poly [ADP-ribose] polymerase 1 0.026 0.12 DNA 0 
MCM5 DNA replication licensing factor MCM5 0.035 0.28 DNA 6.29e-161 
SMRC2 SWI/SNF complex subunit SMARCC2 0.038 0.47 DNA 0 
PDS5B Sister chromatid cohesion protein PDS5 homolog 
B 
0.0041 0.16 DNA 7.86e-164 
RFA1 Replication protein A 70 kDa DNA-binding 
subunit 
0.040 0.14 DNA 2.79e-271 
BRD4 Bromodomain-containing protein 4 0.038 0.28 DNA 2.36e-59 
RCC2 Protein RCC2 0.043 0.16 DNA 0 
EDF1         Endothelial differentiation-related factor 1 0.035 0.47 other 5.55e-30 
GMPPA Mannose-1-phosphate guanyltransferase alpha 0.022 0.15 RNA 2.68e-12 
MCES mRNA cap guanine-N7 methyltransferase 0.034 0.30 RNA 3.64e-64 
KHDR2 KH domain-containing, RNA-binding, signal 
transduction-associated protein 2 




PRP4 U4/U6 small nuclear ribonucleoprotein Prp4 0.042 0.23 RNA 5.59e-67 
RBM12 RNA-binding protein 12 0.014 0.27 RNA 1.02e-119 
MTA70 N6-adenosine-methyltransferase 70 kDa subunit 0.035 0.13 RNA 4.86e-42 
DX39A ATP-dependent RNA helicase DDX39A 0.0064 0.26 RNA 6.11e-210 
RL10A 60S ribosomal protein L10a 0.0147 0.11 RNA 1.16e-111 
MCA3 Eukaryotic translation elongation factor 1 epsilon-
1 
0.016 0.18 RNA 4.51e-28 
 
THOC4 THO complex subunit 4 0.028 0.35 RNA 1.23e-269 
SYK Lysine--tRNA ligase 0.013 0.13 RNA 6.43e-154 
RS2 40S ribosomal protein S2 0.018 0.14 RNA 8.09e-160 
EIF3L Eukaryotic translation initiation factor 3 subunit L 0.027 0.12 RNA 3.88e-244 
RL21 60S ribosomal protein L21 0.028 0.24 RNA 2.68e-71 
HNRH2 Heterogeneous nuclear ribonucleoprotein H2 0.014 0.23 RNA 0 
EIF3C Eukaryotic translation initiation factor 3 subunit C 0.034 0.14 RNA 5.57e-146 
CPSF3 Cleavage and polyadenylation specificity factor 
subunit 3 
0.017 0.24 RNA 3.37e-101 
RL5 60S ribosomal protein L5 0.030 0.14 RNA 2.23e-174 
PSPC1 Paraspeckle component 1 0.043 0.21 RNA 5.04e-258 
RBM8A RNA-binding protein 8A 0.022 0.31 RNA 2.03e-240 
HNRPK Heterogeneous nuclear ribonucleoprotein K 0.026 -0.55 RNA 0 
DDX18 ATP-dependent RNA helicase DDX18 0.044 0.22 RNA 8.05e-51 








Table B2 HT2 (24 hours post treatment), Differentially expressed protein groups mapped to Panther protein 
class: nucleic acid binding (PC000171) 
geneID gene.name p.value log2FC* subtype PEP
SMRD3 SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily D member 3 
0.017 -0.20 DNA 1.04e-48 
TBPL1 TATA box-binding protein-like protein 1 0.019 0.085 DNA 2.97e-58 
ZNF24 Zinc finger protein 24 0.001 0.19 DNA 8.49e-05 
IF5 Eukaryotic translation initiation factor 5 0.015 -0.062 RNA 1.40e-130 
CHTOP Chromatin target of PRMT1 protein 0.0040 -0.074 RNA 1.24e-91 
EIF3G Eukaryotic translation initiation factor 3 subunit G 0.032 -0.085 RNA 4.00e-133 
RS16 40S ribosomal protein S16 0.018 -0.11 RNA 2.23e-47 
ZFHX3 Zinc finger homeobox protein 3 0.032 -0.11 RNA 1.66e-13 
RU17 U1 small nuclear ribonucleoprotein 70 kDa 0.043 -0.13 RNA 4.91e-130 
EFTU Elongation factor Tu, mitochondrial 0.032 -0.13 RNA 0 
SYCC Cysteine--tRNA ligase, cytoplasmic 0.033 -0.16 RNA 5.80e-85 
DDX18 ATP-dependent RNA helicase DDX18 0.030 -0.29 RNA 8.06e-51 
WDR7 WD repeat-containing protein 7 0.043 -0.29 RNA 1.43e-15 





LRRF1 Leucine-rich repeat flightless-interacting protein 1 0.014 0.063 RNA 1.37e-13 
 
MRT4 mRNA turnover protein 4 homolog 0.028 0.26 RNA 1.51e-26 
 
EXOS8 Exosome complex component RRP43 0.022 0.28 RNA 8.78e-75 
 
ERI3 ERI1 exoribonuclease 3 0.001 0.45 RNA 2.85e-15 
 




Table B3 HT3 (48 hours post treatment), Differentially expressed protein groups mapped to Panther protein  
class: nucleic acid binding (PC000171) 
geneID gene.name p.value log2FC* subtype PEP 
ATPB ATP synthase subunit beta, mitochondrial 0.028 -0.046 DNA 0 
LN28B Protein lin-28 homolog B 0.0039 0.14 DNA 1.0045e-10 
 
HMGB2 High mobility group protein B2 0.015 0.34 DNA 3.7012e-24 
 
SMRD1 SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily D member 1 
0.025 0.12 DNA 3.2527e-191 
 
MSH2 DNA mismatch repair protein Msh2 0.036 0.21 DNA 2.0168e-159 
 
RUXF Small nuclear ribonucleoprotein F 0.043 0.53 RNA 2.1771e-80 
 
PRP16 Pre-mRNA-splicing factor ATP-dependent RNA 
helicase PRP16 
0.021 0.42 RNA 1.1609e-39 
 
117 
SREK1 Splicing regulatory glutamine/lysine-rich protein 1 0.042 0.1 RNA 1.8535e-49 
RL13 60S ribosomal protein L13 0.037 0.34 RNA 1.1597e-115 
CHTOP Chromatin target of PRMT1 protein 0.024 0.27 RNA 1.2434e-91 
IF2B1 Insulin-like growth factor 2 mRNA-binding protein 1 0.042 0.27 RNA 0 
*FC- fold change, HIV-Tat/ BME (i.e. treated/control)
Table B4 HT1 (6 hours post treatment), Differentially expressed protein groups mapped to Panther protein 
class: cytoskeletal protein (PC00085) 
geneID gene.name p.value log2FC* subtype PEP 
MCA3 Eukaryotic translation elongation 
factor 1 epsilon-1 
0.016 0.18 actin 4.51e-28 
CTNA1 Catenin alpha-1 0.037 -0.23 actin 0 
DEST Destrin 0.0063 0.32 actin 1.58e-49 
LMNA Prelamin-A/C 0.030 0.20 intermediary 
filament 
1.52e-44 
*FC- fold change, HIV-Tat/ BME (i.e. treated/control)
Table B5 HT2 (24 hours post treatment), Differentially expressed protein groups mapped to Panther protein 
class: cytoskeletal protein (PC00085) 
geneID gene.name p.value log2FC* subtype PEP 
ARP10 Actin-related protein 10 0.023 -0.079 actin 6.00e-129 
FMN2 Formin-2 0.0047 -0.46 actin 4.71e-18 
118 
ZFHX3 Zinc finger homeobox protein 3 0.032 -0.11 actin 1.66e-13 
TWF1 Twinfilin-1 0.026 -0.11 actin 8.50e-141 
ADDA Alpha-adducin 0.032 -0.16 actin 1.17e-121 
OPA1 Dynamin-like 120 kDa protein, 
mitochondrial 
0.022 -0.13 microtubule 8.28e-127
GCP3 Gamma-tubulin complex component 3 0.017 -0.19 microtubule 3.79e-26
KLC2 Kinesin light chain 2 0.0053 -0.18 microtubule 8.14e-106
MAP1S Microtubule-associated protein 1S 0.033 -0.18 microtubule 1.79e-115
*FC- fold change, HIV-Tat/ BME (i.e. treated/control)
Table B6 HT3 (48 hours post treatment), Differentially expressed protein groups 
mapped to Panther protein class: cytoskeletal protein (PC00085) 
geneID gene.name p.value log2FC* subtype PEP 
CTNA1 Catenin 
alpha-1 
0.031 -0.15 actin 0 
CTNA2 Catenin 
alpha-2 
0.038 -0.19 actin 0 




11.3 Appendix C  
Repeat of 24-hour time point  
 
Tables C1 and C2 list protein groups and their details for those that mapped to 
Panther protein class cytoskeletal protein (PC00085) and nucleic acid binding 
(PC000171).  
 
Table C1 Differentially expressed protein groups mapped to Panther protein class: 
cytoskeletal protein (PC00085) 
geneID gene.name log2FC* p.value subtype PEP 





























Nuclear lamina 8.0e-90 
 











SPTBN1 Spectrin beta chain, 
non-erythrocytic 
-0.10 0.030 actin 0 
PLEC Plectin -0.13 
 
0.037 cytolinker 1.4e-109 
 





Table C2 Differentially expressed protein groups mapped to Panther protein class: nucleic acid 
binding (PC000171) 
geneID gene.name p.value Log2FC subtype PEP 












EIF3E Eukaryotic translation initiation factor 

























ribonucleoprotein M   














DDX17 Probable ATP-dependent RNA 
































HNRPD Isoform 3 of Heterogeneous nuclear 







PRKRA Interferon-inducible double-stranded 





























11.4 Appendix D 
Time course repeat at lower (70%) cell confluence 
Panther protein class outputs, per time point, can be viewed in Tables D1-4 
(cytoskeletal protein) and D5-7 (nucleic acid binding proteins).  
Table D1 Time point 1, Differentially expressed protein groups mapped to Panther protein 
class: cytoskeletal protein (PC00085) 
geneID gene.name p.value log2FC* PEP 
STML2 Stomatin-like protein 2, 
mitochondrial 
0.010 -0.52 7.91e-58 
*FC- fold change, HIV-Tat/ control
Table D2 Time point 2, Differentially expressed protein groups mapped to Panther protein 
class: cytoskeletal protein (PC00085) 
geneID gene.name p.value log2FC* PEP
CSRP1 Cysteine and glycine-rich protein 1  0.010 0.31 1.8e-35 
DC1L2 Cytoplasmic dynein 1 light 
intermediate chain 2  
0.012 -0.066 4.9e-125 
TLN1 Talin-1 0.016 0.16 9.9e-169 
KIF5C Kinesin heavy chain isoform 5C 0.035 -0.14 0 
*FC- fold change, HIV-Tat/ control
Table D3 Time point 3, Differentially expressed protein groups mapped to Panther protein 
class: cytoskeletal protein (PC00085) 
geneID gene.name p.value log2FC* PEP 
COF1 HUMAN Cofilin-1 0.036 -0.22 0 
SHLB1 HUMAN Endophilin-B1 0.038 -0.37 5.3e-28 
CLIC4 HUMAN Chloride intracellular 
channel protein 4 
0.039 -0.16 1.4e-
208 




*FC- fold change, HIV-Tat/ control
Table D4 Time point 1, Differentially expressed protein groups mapped to Panther protein 
class: nucleic acid binding (PC000171) 
geneID gene.name p.value log2FC* subtype PEP
CHD7 Chromodomain-helicase-
DNA-binding protein 7 
0.011 0.30 DNA 8.47e-24 
RAD21 Double-strand-break repair 
protein rad21 homolog  
0.015 -0.55 DNA 4.8e-95 
NXF1 Nuclear RNA export factor 1 0.016 -0.36 RNA 5.8e-54 




like protein LSm2  
SUGP2 SURP and G-patch domain-
containing protein 2  
0.022 -0.40 RNA 2.3e-108 
H12 Histone H1,2  0.027 -0.41 DNA 0 
ROA2 Heterogeneous nuclear 
ribonucleoproteins A2/B1  
0.028 -0.33 RNA 0 
VATB2 V-type proton ATPase subunit 
B, brain isoform  
0.034 -0.36 DNA 3.9e-149 
H2A1J Histone H2A type 1-J  0.034 -1.25 DNA 7.4e-152 
ATPA ATP synthase subunit alpha, 
mitochondrial  
0.045 -0.36 DNA 0 
SRSF3 Isoform 2 of Serine/arginine-
rich splicing factor 3  
0.047 -0.42 RNA 1.2e-113 
*FC- fold change, HIV-Tat/ control 
 
 
Table D5 Time point 2, Differentially expressed protein groups mapped to Panther  
protein class: nucleic acid binding (PC000171) 
geneID gene.name log2FC* p.value subtype PEP 
CBX8 Chromobox protein 
homolog 8  
0.26 0.0033 DNA 4.6e-10 
SRS10 Isoform 5 of 
Serine/arginine-rich 
splicing factor 10  
0.43 0.0049 RNA 2.3e-56 
DKC1 H/ACA 
ribonucleoprotein 
complex subunit 4  
0.12 0.0062 RNA/ DNA 1.7e-72 
COT1 COUP transcription 
factor 1 
0.44 0.0094 DNA 2.2e-88 
THOC4 THO complex subunit 4 0.15 0.011 RNA 2.6e-227 




0.10 0.012 RNA 0 
RS17L 40S ribosomal protein 
S17-like  
0.11 0.014 RNA 1.6e-42 
DHX9 ATP-dependent RNA 
helicase A  
0.05 0.014 RNA 0 
TIAR Nucleolysin TIAR  0.44 0.021 RNA 1.4e-76 
MTA2 Metastasis-associated 
protein MTA2  
0.19 0.021 DNA 1.1e-84 
DNLI3 DNA ligase 3  0.33 0.024 DNA 1.7e-61 
HNRPK Isoform 3 of 
Heterogeneous nuclear 
ribonucleoprotein K  
0.31 0.028 DNA 0 
FUS Isoform Short of RNA-
binding protein FUS  
0.26 0.029 DNA 0 
BAZ1B Isoform 2 of Tyrosine-
protein kinase BAZ1B  
0.27 0.036 DNA 3.7e-104 
PRKRA Interferon-inducible 
double-stranded RNA-
dependent protein kinase 
activator A  
0.15 0.039 RNA 1.6e-33 
123 
POGZ Isoform 5 of Pogo 
transposable element 
with ZNF domain  
0.28 0.039 DNA 4.4e-83 
NOP58 Nucleolar protein 58 0.23 0.042 RNA 2.5e-137 
YLPM1 YLP motif-containing 
protein 1  
0.23 0.045 DNA 4.5e-125 
*FC- fold change, HIV-Tat/ control
Table D6 Time point 3, Differentially expressed protein groups mapped to Panther protein 
class: nucleic acid binding (PC000171) 
geneID gene.name log2FC* p.value subtype PEP
PRP31 U4/U6 small nuclear 
ribonucleoprotein Prp31 
-0.29 0.0038 RNA 4.6e-34 
IF4E Eukaryotic translation 
initiation factor 4E  
-0.35 0.0039 RNA 3.5e-54 
LARP7 La-related protein 7 -0.22 0.0065 DNA 9.8e-65 
CPSF5 Cleavage and 
polyadenylation specificity 
factor subunit 5  
-0.19 0.0072 RNA 6.4e-121 
IF1AX Eukaryotic translation 
initiation factor 1A, X-
chromosomal 
-0.39 0.011 RNA 1.5e-39 
PSPC1 Paraspeckle component 1 -0.25 0.012 DNA 1.2e-151 
CRNL1 Isoform 2 of Crooked neck-
like protein 1 
-0.38 0.013 RNA 1.6e-32 
SMRCD Isoform 3 of SWI/SNF-
related matrix-associated 
actin-dependent regulator of 
chromatin subfamily A 
containing DEAD/H box 1  
-0.27 0.013 DNA 1.0e-25 
CPSF7 Isoform 2 of Cleavage and 
polyadenylation specificity 
factor subunit 7 
-0.24 0.014 RNA 2.5e-94 
RL36L 60S ribosomal protein L36a-
like  
-0.26 0.017 RNA 3.5e-31 
MTA2 Metastasis-associated protein 
MTA2 
-0.14 0.018 DNA 1.1e-84 
C2AIL CDKN2AIP N-terminal-like 
protein  
0.58 0.019 DNA 2.2e-24 
SYFB Phenylalanine--tRNA ligase 
beta subunit 
-0.22 0.019 RNA 2.8e-50 
ZCCHL Zinc finger CCCH-type 
antiviral protein 1-like  
-0.26 0.020 DNA/ 
RNA 
1.8e-32 
ZN207 Isoform 2 of BUB3-
interacting and GLEBS 
motif-containing protein 
ZNF207 
-0.45 0.025 DNA 9.0e-74 
SMRD3 Isoform 2 of SWI/SNF-
related matrix-associated 
actin-dependent regulator of 
chromatin subfamily D 
member 3  
-0.23 0.026 DNA 2.7e-40 
124 
IF4A3 Eukaryotic initiation factor 
4A-III 
-0.19 0.026 RNA 2.1e-243 
PRKRA Interferon-inducible double-
stranded RNA-dependent 
protein kinase activator A  
-0.40 0.027 RNA 1.6e-33 
CBX5 Chromobox protein homolog 
5 
-0.27 0.027 DNA 1.5e-95 
SF3B1 Splicing factor 3B subunit 1 -0.18 0.029 RNA 0 
DSRAD Isoform 5 of Double-stranded 
RNA-specific adenosine 
deaminase 
0.29 0.032 RNA 1.5e-155 
UBP24 Ubiquitin carboxyl-terminal 
hydrolase 24  
-0.25 0.035 1.2e-27 
EHMT1 Histone-lysine N-
methyltransferase EHMT1 
-0.16 0.036 DNA 2.0e-24 
CLIC4 Chloride intracellular 
channel protein 4  
-0.16 0.039 1.4e-208 
ZFR Zinc finger RNA-binding 
protein 
-0.22 0.041 RNA 7.1e-128 
RL3 60S ribosomal protein L3 -0.20 0.042 RNA 3.4e-131 
RBM25 RNA-binding protein 25 -0.26 0.044 RNA 6.0e-80 
*FC- fold change, HIV-Tat/ control
